

Maciej Banach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/808988/publications.pdf>

Version: 2024-02-01

978
papers

153,390
citations

863

117
h-index

87

360
g-index

1020
all docs

1020
docs citations

1020
times ranked

119632
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment goal attainment for secondary prevention in coronary patients with or without diabetes mellitus – Polish multicenter study POLASPIRE. Archives of Medical Science, 2023, 19, 305-312.	0.4	5
2	Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies. Archives of Medical Science, 2023, 19, 1214-1227.	0.4	2
3	Harnessing polyphenol power by targeting eNOS for vascular diseases. Critical Reviews in Food Science and Nutrition, 2023, 63, 2093-2118.	5.4	10
4	Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovascular Research, 2023, 118, 3288-3304.	1.8	57
5	Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From ADA VINCI. Cardiovascular Drugs and Therapy, 2023, 37, 941-953.	1.3	6
6	Poor adherence to lifestyle recommendations in patients with coronary heart disease: results from the EUROASPIRE surveys. European Journal of Preventive Cardiology, 2022, 29, 383-395.	0.8	40
7	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. European Heart Journal, 2022, 43, 830-833.	1.0	92
8	Role of confirmed and potential predictors of an unfavorable outcome in heart failure in everyday clinical practice. Irish Journal of Medical Science, 2022, 191, 213-227.	0.8	6
9	Negatively-charged Liposome Nanoparticles Can Prevent Dyslipidemia and Atherosclerosis Progression in the Rabbit Model. Current Vascular Pharmacology, 2022, 20, 69-76.	0.8	4
10	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	0.8	220
11	Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019. Lancet Infectious Diseases, The, 2022, 22, 222-241.	4.6	53
12	The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis. Seminars in Cancer Biology, 2022, 86, 951-959.	4.3	22
13	Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials. British Journal of Clinical Pharmacology, 2022, 88, 1520-1528.	1.1	17
14	Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. European Journal of Preventive Cardiology, 2022, 28, 1864-1872.	0.8	19
15	Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. European Journal of Preventive Cardiology, 2022, 29, 328-339.	0.8	27
16	Cellular senescence, telomeres, and cardiovascular risk in familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2022, 29, 718-720.	0.8	5
17	Extreme cardiovascular risk – do we need a new risk category?. European Heart Journal, 2022, 43, 1784-1786.	1.0	11
18	Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test. Diabetes Research and Clinical Practice, 2022, 183, 109156.	1.1	1

#	ARTICLE	IF	CITATIONS
19	The current use and evolving landscape of nutraceuticals. <i>Pharmacological Research</i> , 2022, 175, 106001.	3.1	63
20	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , 2022, 42, 261-271.	1.5	5
21	Can We Use mTOR Inhibitors for COVID-19 Therapy?. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 1805-1808.	0.6	4
22	The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Oncology</i> , The, 2022, 23, 27-52.	5.1	90
23	Prevalence of statin intolerance: a meta-analysis. <i>European Heart Journal</i> , 2022, 43, 3213-3223.	1.0	151
24	Discordance between LDL-C and Apolipoprotein B Levels and Its Association with Renal Dysfunction: Insights from a Population-Based Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 313.	1.0	2
25	Relationship between Low-Density Lipoprotein Cholesterol, Lipid Lowering Agents and the Risk of Stroke: A meta-analysis of Observational studies (n=355,591) and Randomized Controlled Trials (n=165,988).. <i>Archives of Medical Science</i> , 2022, , .	0.4	2
26	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. <i>Biomarker Insights</i> , 2022, 17, 117727192110667.	1.0	1
27	Dyslipidemia and Diabetes. , 2022, , 341-360.		1
28	Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials. <i>Nutrients</i> , 2022, 14, 256.	1.7	76
29	Relationship between physical capacity and depression in heart failure patients undergoing hybrid comprehensive telerehabilitation vs. usual care: subanalysis from the TELEREH-HF Randomized Clinical Trial. <i>European Journal of Cardiovascular Nursing</i> , 2022, 21, 568-577.	0.4	4
30	Protective role of nutraceuticals against myocarditis. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112242.	2.5	16
31	Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 868-880.	2.2	38
32	The effect of trehalose administration on vascular inflammation in patients with coronary artery disease. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112632.	2.5	5
33	Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 815-816.	0.8	1
34	Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia. <i>Lipids in Health and Disease</i> , 2022, 21, 21.	1.2	10
35	A short history of the European Association of Preventive Cardiology (EAPC). <i>European Journal of Preventive Cardiology</i> , 2022, , .	0.8	1
36	Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. <i>JAMA Oncology</i> , 2022, 8, 420.	3.4	719

#	ARTICLE	IF	CITATIONS
37	Fibrinogen and Atherosclerotic Cardiovascular Diseasesâ€”Review of the Literature and Clinical Studies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 193.	1.8	44
38	Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 820260.	1.1	27
39	Heart Failure Risk Predictions and Prognostic Factors in Adults With Congenital Heart Diseases. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 692815.	1.1	4
40	Biochemical and cardiovascular predictors of PIMS-TS risk in children after COVID-19 recovery: preliminary results of the LATE-COVID-Kids Study. <i>Archives of Medical Science</i> , 2022, 18, 545-552.	0.4	4
41	Contemporary Management of Dyslipidemia. <i>Drugs</i> , 2022, 82, 559-576.	4.9	14
42	The role of adiposity, diet and inflammation on the discordance between LDL-C and apolipoprotein B. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 605-615.	1.1	8
43	Which patients at risk of cardiovascular disease might benefit the most from inclisiran? â€” The expert opinion of the Polish experts. The compromise between EBM and possibilities in healthcare.. <i>Archives of Medical Science</i> , 2022, 18, 569-576.	0.4	9
44	Prognostic Impact of Hybrid Comprehensive Telerehabilitation Regarding Diastolic Dysfunction in Patients with Heart Failure with Reduced Ejection Fractionâ€”Subanalysis of the TELEREH-HF Randomized Clinical Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 1844.	1.0	0
45	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2022, 16, 286-297.	0.6	20
46	Heart Failure Patientsâ€™ Adherence to Hybrid Comprehensive Telerehabilitation and Its Impact on Prognosis Based on Data from TELEREH-HF Randomized Clinical Trial. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 2595.	1.3	1
47	Stepâ€”step diagnosis and management of the nocebo/drucebo effect in statinâ€”associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1596-1622.	2.9	35
48	Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study. <i>BMJ, The</i> , 2022, 376, e068208.	3.0	73
49	The detrimental impact of elevated Ferritin to Iron ratio on in-hospital prognosis of patients with COVID-19. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 469-478.	1.5	7
50	Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis. <i>Nutrients</i> , 2022, 14, 1331.	1.7	11
51	Attenuation of isoprenaline-induced myocardial infarction by <i>Rheum turkestanicum</i> . <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112775.	2.5	8
52	Global, regional, and national burden of colorectal cancer and its risk factors, 1990â€”2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 627-647.	3.7	177
53	The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990â€”2019: Findings from the Global Burden of Disease Study 2019. <i>Lancet Regional Health - Europe, The</i> , 2022, 16, 100341.	3.0	70
54	Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE. <i>Archives of Medical Science</i> , 2022, 18, 285-292.	0.4	13

#	ARTICLE	IF	CITATIONS
55	A close-up view of dynamic biomarkers in the setting of COVID-19: Striking focus on cardiovascular system. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 274-286.	1.6	11
56	Oxidative Stress Markers in Hypertrophic Cardiomyopathy. <i>Medicina (Lithuania)</i> , 2022, 58, 31.	0.8	9
57	Prevalence and impact of diabetes in hospitalized COVID-19 patients: A systematic review and meta-analysis. <i>Journal of Diabetes</i> , 2022, 14, 144-157.	0.8	29
58	Assessing the probability of risk factor control in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1465-1475.	0.8	9
59	Coenzyme Q10 Reduces Infarct Size in Animal Models of Myocardial Ischemia-Reperfusion Injury: A Meta-Analysis and Summary of Underlying Mechanisms. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 857364.	1.1	6
60	Biological and practical considerations regarding circadian rhythm and mental health relationships among nurses working night shifts: a narrative review and recommendations.. <i>Rivista Di Psichiatria</i> , 2022, 57, 67-79.	0.6	3
61	Dyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?. <i>Current Atherosclerosis Reports</i> , 2022, 24, 547-556.	2.0	17
62	Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label) <i>Tj ETQq0 0 0 rg07 /Overlook 10 Tf 5</i>	0.7	10
63	Effect of Statins on Prevalence and Mortality of Influenza Virus Infection: A Systematic Review and Meta-Analysis. <i>Archives of Medical Science</i> , 2022, 18, 1-44.	0.4	12
64	The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study. <i>Archives of Public Health</i> , 2022, 80, 142.	1.0	9
65	Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?. <i>Frontiers in Nutrition</i> , 2022, 9, .	1.6	12
66	Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2022, 399, 2129-2154.	6.3	91
67	The spoils of war and the long-term spoiling of health conditions of entire nations. <i>Atherosclerosis</i> , 2022, 352, 76-79.	0.4	2
68	Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	4
69	The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	9
70	Adolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019. <i>Lancet Public Health, The</i> , 2022, 7, e657-e669.	4.7	34
71	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 370-379.	0.8	83
72	Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 205-215.	2.3	45

#	ARTICLE	IF	CITATIONS
73	Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 60, 175-199.	2.9	169
74	↑ higher ratio of serum uric acid to serum creatinine could predict the risk of total and cause specific mortality- insight from a US national survey. <i>International Journal of Cardiology</i> , 2021, 326, 189-193.	0.8	13
75	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). <i>Clinical Nutrition</i> , 2021, 40, 255-276.	2.3	75
76	Resveratrol: Mechanistic and therapeutic perspectives in pulmonary arterial hypertension. <i>Pharmacological Research</i> , 2021, 163, 105287.	3.1	49
77	Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 " can we end this viral series?. <i>Archives of Medical Science</i> , 2021, 17, 275-284.	0.4	6
78	Prognostic value of coronary artery calcium score, area, and density among individuals on statin therapy vs. non-users: The coronary artery calcium consortium. <i>Atherosclerosis</i> , 2021, 316, 79-83.	0.4	37
79	The effect of caloric restriction and fasting on cancer. <i>Seminars in Cancer Biology</i> , 2021, 73, 30-44.	4.3	27
80	Socioeconomic characteristics of patients with coronary heart disease in relation to their cardiovascular risk profile. <i>Heart</i> , 2021, 107, 799-806.	1.2	9
81	Longer sleep duration may negatively affect renal function. <i>International Urology and Nephrology</i> , 2021, 53, 325-332.	0.6	6
82	Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes. <i>Atherosclerosis</i> , 2021, 316, 58-65.	0.4	26
83	Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel. <i>Diabetes Research and Clinical Practice</i> , 2021, 172, 108535.	1.1	14
84	More Good News on Statins and COVID-19. <i>American Journal of Cardiology</i> , 2021, 138, 127-128.	0.7	10
85	HDL and cancer - causality still needs to be confirmed? Update 2020. <i>Seminars in Cancer Biology</i> , 2021, 73, 169-177.	4.3	29
86	The Use of Aspirin in Contemporary Primary Prevention of Atherosclerotic Cardiovascular Diseases Revisited: The Increasing Need and Call for a Personalized Therapeutic Approach. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 139-151.	1.0	6
87	Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19. <i>Angiology</i> , 2021, 72, 122-130.	0.8	20
88	Cardiac manifestations of COVID-19. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 365.	0.5	19
89	Protective Effects of Curcumin Phytosomes Against High-Fat Diet-Induced Atherosclerosis. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1308, 37-44.	0.8	6
90	Effects of statins on mitochondrial pathways. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 237-251.	2.9	94

#	ARTICLE	IF	CITATIONS
91	Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12200.	1.8	53
92	Rationale for Effective Prophylaxis Against COVID-19 Through Simultaneous Blockade of Both Endosomal and Non-Endosomal SARS-CoV-2 Entry into Host Cell. <i>Clinical and Translational Science</i> , 2021, 14, 431-433.	1.5	5
93	Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants. <i>Annals of Medicine</i> , 2021, 53, 1228-1243.	1.5	16
94	PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study. <i>Archives of Medical Science</i> , 2021, 17, 241-244.	0.4	12
95	Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys. <i>Cardiovascular Diabetology</i> , 2021, 20, 38.	2.7	17
96	An aetiology-based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) trial. <i>ESC Heart Failure</i> , 2021, 8, 1263-1273.	1.4	7
97	Renal Denervation for Uncontrolled and Resistant Hypertension: Systematic Review and Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 782.	1.0	5
98	Does trastuzumab-related cardiotoxicity influence long-term outcome in patients with HER-2 positive breast cancer? A prospective study. <i>Archives of Medical Science</i> , 2021, , .	0.4	0
99	Lipid-lowering therapies: Better together. <i>Atherosclerosis</i> , 2021, 320, 86-88.	0.4	23
100	Cost-effectiveness of telerehabilitation in patients with heart failure in Poland: an analysis based on the results of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) randomized clinical trial. <i>Kardiologia Polska</i> , 2021, 79, 510-516.	0.3	7
101	The role of statins in lung cancer. <i>Archives of Medical Science</i> , 2021, 18, 141-152.	0.4	11
102	PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis. <i>Archives of Medical Science</i> , 2021, 17, 1365-1377.	0.4	39
103	Left Ventricular Diastolic Dysfunction as Predictor of Unfavorable Prognosis After ESUS. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 617-627.	1.1	2
104	Editorial: Telemedicine During and Beyond COVID-19. <i>Frontiers in Public Health</i> , 2021, 9, 662617.	1.3	39
105	Drucebo effect – the challenge we should all definitely face!. <i>Archives of Medical Science</i> , 2021, 17, 542-543.	0.4	13
106	Molecularly targeted nanoparticles: an emerging tool for evaluation of expression of the receptor for advanced glycation end products in a murine model of peripheral artery disease. <i>Cellular and Molecular Biology Letters</i> , 2021, 26, 10.	2.7	5
107	Foam Cells as Therapeutic Targets in Atherosclerosis with a Focus on the Regulatory Roles of Non-Coding RNAs. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2529.	1.8	42
108	Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. <i>ELife</i> , 2021, 10, .	2.8	41

#	ARTICLE	IF	CITATIONS
109	Smoking cessation in patients with established coronary artery disease: data from the POLASPIRE survey. <i>Kardiologia Polska</i> , 2021, 79, 418-425.	0.3	3
110	Omega-6 fatty acids and the Risk of Cardiovascular Disease: Insights from a Systematic Review and Meta-Analysis of Randomized Controlled Trials and a Mendelian Randomization Study.. <i>Archives of Medical Science</i> , 2021, 18, 466-479.	0.4	3
111	Novel Therapeutical Approaches to Managing Atherosclerotic Risk. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4633.	1.8	23
112	Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2021, 166, 105499.	3.1	62
113	Antiarrhythmic effect of 9-week hybrid cardiac telerehabilitation - subanalysis of the TELEREhabilitation in Heart Failure patients - TELEREH-HF randomized clinical trial. <i>Europace</i> , 2021, 23, .	0.7	1
114	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021, 325, 99-109.	0.4	83
115	COVID-19 and cardiovascular complications – the preliminary results of the LATE-COVID study. <i>Archives of Medical Science</i> , 2021, 17, 818-822.	0.4	39
116	The Relationship of Dehydration and Body Mass Index With the Occurrence of Atrial Fibrillation in Heart Failure Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 668653.	1.1	3
117	Effects of hybrid comprehensive telerehabilitation on cardiopulmonary capacity in heart failure patients depending on diabetes mellitus: subanalysis of the TELEREH-HF randomized clinical trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 106.	2.7	10
118	Serum anti-inflammatory and inflammatory markers have no causal impact on telomere length: a Mendelian randomization study. <i>Archives of Medical Science</i> , 2021, 17, 739-751.	0.4	8
119	Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications. <i>ESC Heart Failure</i> , 2021, 8, 2397-2418.	1.4	18
120	Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies. <i>Current Atherosclerosis Reports</i> , 2021, 23, 32.	2.0	11
121	Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. <i>Archives of Medical Science</i> , 2021, 17, 579-595.	0.4	61
122	Antiarrhythmic effect of 9-week hybrid comprehensive telerehabilitation and its influence on cardiovascular mortality in long-term follow-up – subanalysis of the TELEREhabilitation in Heart Failure Patients randomized clinical trial. <i>Archives of Medical Science</i> , 2021, 18, 293-306.	0.4	0
123	Is COVID-19 Another Case of Obesity Paradox? - Results from An International Ecological Study on behalf of the REPROGRAM Consortium Obesity Study Group. <i>Archives of Medical Science</i> , 2021, , .	0.4	2
124	Targeting AMPK by Statins: A Potential Therapeutic Approach. <i>Drugs</i> , 2021, 81, 923-933.	4.9	54
125	May Measurement Month 2019: an analysis of blood pressure screening results from Poland. <i>European Heart Journal Supplements</i> , 2021, 23, B124-B127.	0.0	2
126	Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>Lancet Public Health</i> , The, 2021, 6, e482-e499.	4.7	38

#	ARTICLE	IF	CITATIONS
127	Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2021, 191, 1385-1397.	1.9	62
128	Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study. Lancet HIV, 2021, 8, e363-e375.	2.1	32
129	The International Lipid Expert Panel (ILEP) – the role of “optimal” collaboration in the effective diagnosis and treatment of lipid disorders. European Heart Journal, 2021, 42, 3817-3820.	1.0	3
130	The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidylpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes. Journal of Diabetes Research, 2021, 2021, 1-10.	1.0	9
131	Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations. European Heart Journal, 2021, 42, 4787-4788.	1.0	27
132	Quercetin and metabolic syndrome: A review. Phytotherapy Research, 2021, 35, 5352-5364.	2.8	138
133	Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000–2018. Nature Human Behaviour, 2021, 5, 1027-1045.	6.2	24
134	Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. BMC Medicine, 2021, 19, 139.	2.3	22
135	PCSK9 vaccine: so near, yet so far!. European Heart Journal, 2021, 42, 4007-4010.	1.0	23
136	Fetal toxicity associated with statins: A systematic review and meta-analysis. Atherosclerosis, 2021, 327, 59-67.	0.4	30
137	Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet, The, 2021, 397, 2337-2360.	6.3	609
138	Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates. Vaccines, 2021, 9, 749.	2.1	24
139	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	1.6	39
140	Potential for optimizing management of obesity in the secondary prevention of coronary heart disease. European Heart Journal Quality of Care & Clinical Outcomes, 2021, , .	1.8	5
141	On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management. Archives of Medical Science, 2021, 17, 954-964.	0.4	15
142	Effects of statins on myocarditis: A review of underlying molecular mechanisms. Progress in Cardiovascular Diseases, 2021, 67, 53-64.	1.6	23
143	Factors and Prognostic Significance of Impaired Exercise Tolerance in Women over 40 with Arterial Hypertension. Journal of Personalized Medicine, 2021, 11, 759.	1.1	1
144	Genetically Higher Level of Mannose Has No Impact on Cardiometabolic Risk Factors: Insight from Mendelian Randomization. Nutrients, 2021, 13, 2563.	1.7	1

#	ARTICLE	IF	CITATIONS
145	Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0008824.	1.3	10
146	Postmarketing nutriviigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. <i>Archives of Medical Science</i> , 2021, 17, 856-863.	0.4	19
147	How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 65-74.	1.6	23
148	Open Up your Science in <i>EHJ Open</i>. <i>European Heart Journal Open</i> , 2021, 1, .	0.9	1
149	The results of implementing health education in polish ambulatory care on atherosclerosis risk factors. <i>Atherosclerosis</i> , 2021, 331, e152.	0.4	0
150	Dyslipidemia Management in Patients with Coronary Artery Disease. Data from the POLASPIRE Survey. <i>Journal of Clinical Medicine</i> , 2021, 10, 3711.	1.0	8
151	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
152	Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 57.	2.0	51
153	Compositional and functional properties of high-density lipoproteins in relation to coronary in-stent restenosis. <i>Archives of Medical Science</i> , 2021, , .	0.4	1
154	Measuring routine childhood vaccination coverage in 204 countries and territories, 1980â€“2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. <i>Lancet, The</i> , 2021, 398, 503-521.	6.3	93
155	INTERASPIRE: an International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions. <i>Current Cardiology Reports</i> , 2021, 23, 136.	1.3	5
156	Statins as anti-pyrototic agents. <i>Archives of Medical Science</i> , 2021, 17, 1414-1417.	0.4	31
157	Are risk-based LDL-c goals achieved in primary and secondary care in central and Eastern Europe? comparison with other Europe regions from the DA VINCI observational study. <i>Atherosclerosis</i> , 2021, 331, e23.	0.4	1
158	Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-11.	1.0	5
159	Use of multidimensional item response theory methods for dementia prevalence prediction: an example using the Health and Retirement Survey and the Aging, Demographics, and Memory Study. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 241.	1.5	2
160	Assessment of ECG during hybrid comprehensive telerehabilitation in heart failure patientsâ€”Subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREHâ€“HF) randomized clinical trial. <i>Annals of Noninvasive Electrocardiology</i> , 2021, 26, e12887.	0.5	5
161	Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2021, 398, 870-905.	6.3	229
162	The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis. <i>Current Medicinal Chemistry</i> , 2021, 28, 6066-6081.	1.2	6

#	ARTICLE	IF	CITATIONS
163	Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry. <i>Atherosclerosis</i> , 2021, 333, 16-23.	0.4	19
164	Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis. <i>BioMed Research International</i> , 2021, 2021, 1-20.	0.9	33
165	Hypertensive urgencies during the first wave of COVID-19 pandemic in a tertiary hospital setting: A shaped alarming curve.. <i>Archives of Medical Science</i> , 2021, , .	0.4	4
166	Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4472.	1.0	2
167	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021, 398, 1713-1725.	6.3	142
168	RNA Silencing in the Management of Dyslipidemias. <i>Current Atherosclerosis Reports</i> , 2021, 23, 69.	2.0	19
169	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. <i>Lancet, The</i> , 2021, 398, 957-980.	6.3	1,289
170	Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland. <i>Journal of Clinical Medicine</i> , 2021, 10, 4302.	1.0	10
171	Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990â€“2050. <i>Lancet, The</i> , 2021, 398, 1317-1343.	6.3	79
172	Global, regional, and national burden of bone fractures in 204 countries and territories, 1990â€“2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>The Lancet Healthy Longevity</i> , 2021, 2, e580-e592.	2.0	277
173	Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990â€“2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. <i>Lancet HIV,the</i> , 2021, 8, e633-e651.	2.1	56
174	Primary prevention. The cornerstone to reduce the burden of cardiovascular disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 827-828.	0.4	2
175	Global, regional, and national burden of stroke and its risk factors, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Neurology, The</i> , 2021, 20, 795-820.	4.9	2,308
176	Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. <i>Atherosclerosis</i> , 2021, 334, 66-75.	0.4	29
177	A comprehensive review on the lipid and pleiotropic effects of pitavastatin. <i>Progress in Lipid Research</i> , 2021, 84, 101127.	5.3	24
178	A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. <i>Atherosclerosis</i> , 2021, 336, 1-11.	0.4	22
179	Protective Effects of Curcumin on Endothelium: An Updated Review. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1291, 103-119.	0.8	9
180	EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1279-1289.	0.8	369

#	ARTICLE	IF	CITATIONS
181	Statins: Then and Now. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 23.	0.5	54
182	Red Yeast Rice for Hypercholesterolemia. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 192.	0.5	47
183	COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection. <i>Lipids in Health and Disease</i> , 2021, 20, 141.	1.2	27
184	Associations between serum triglycerides and abdominal aortic calcification in a cross-sectional study from the United States of America. <i>European Heart Journal</i> , 2021, 42, .	1.0	1
185	Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel. <i>Journal of Clinical Medicine</i> , 2021, 10, 4930.	1.0	10
186	Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2021, 398, 1593-1618.	6.3	92
187	Management of Statin Intolerance. <i>Contemporary Cardiology</i> , 2021, , 207-218.	0.0	0
188	Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. <i>Nutrients</i> , 2021, 13, .	1.7	1
189	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGram 2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5656.	1.0	9
190	Sleep Duration May Not Have Any Effect on The Risk of Stroke: Insights from Mendelian Randomization and Prospective Cohort Studies. <i>Archives of Medical Science</i> , 2021, , .	0.4	0
191	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. <i>Diagnostyka Laboratoryjna I Wiadomości PTDL</i> , 2021, 57, 1-99.	0.0	0
192	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. <i>Archives of Medical Science</i> , 2021, 17, 1447-1547.	0.4	78
193	Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. <i>Nutrients</i> , 2021, 13, 2957.	1.7	9
194	The Association between Coffee and Caffeine Consumption and Renal Function: Insight from Individual-Level Data, Mendelian Randomization, and Meta-Analysis. <i>Archives of Medical Science</i> , 2021, , .	0.4	1
195	Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 785250.	1.1	11
196	CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities. <i>Metabolites</i> , 2021, 11, 857.	1.3	8
197	Implications of the 2021 ESC Cardiovascular Risk Classification among 283,000 European Immigrants Living in a Low-Risk Region: A Population-Based Analysis in Catalonia. <i>Archives of Medical Science</i> , 2021, , .	0.4	0
198	Patient after correction Taussig–Bing anomaly with severe neo-aortic regurgitation after sudden cardiac arrest. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e05085.	0.2	0

#	ARTICLE	IF	CITATIONS
199	Statins and Lp(a): do not make perfect the enemy of excellent. <i>European Heart Journal</i> , 2020, 41, 190-191.	1.0	15
200	Methotrexate for Cardiovascular Risk Reduction: The Right Choice?. <i>Angiology</i> , 2020, 71, 105-107.	0.8	11
201	Protein convertase subtilisin/kexin type 9 biology in nephrotic syndrome: implications for use as therapy. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1663-1674.	0.4	13
202	Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. <i>Clinical Nutrition</i> , 2020, 39, 1742-1752.	2.3	106
203	A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome. <i>Drug Discovery Today</i> , 2020, 25, 58-72.	3.2	27
204	Tomato and lycopene consumption is inversely associated with total and cause-specific mortality: a population-based cohort study, on behalf of the International Lipid Expert Panel (ILEP). <i>British Journal of Nutrition</i> , 2020, 124, 1303-1310.	1.2	19
205	Genetic testing in familial hypercholesterolaemia: What does it add?. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 105-106.	0.8	9
206	National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. <i>International Journal of Epidemiology</i> , 2020, 49, 173-192.	0.9	44
207	Associations of serum uric acid with total and cause-specific mortality: Findings from individuals and pooling prospective studies. <i>Atherosclerosis</i> , 2020, 296, 49-58.	0.4	27
208	Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1630-1636.	0.8	23
209	Chronic medication intake in patients with stable coronary heart disease across Europe: Evidence from the daily clinical practice. Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry. <i>International Journal of Cardiology</i> , 2020, 300, 7-13.	0.8	9
210	Modulation of microRNAs by aspirin in cardiovascular disease. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 249-254.	2.3	26
211	Impact of serum 25-hydroxyvitamin D 25(OH) on telomere attrition: A Mendelian Randomization study. <i>Clinical Nutrition</i> , 2020, 39, 2730-2733.	2.3	9
212	Regulation of efferocytosis by caspase-dependent apoptotic cell death in atherosclerosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 120, 105684.	1.2	21
213	Low-carbohydrate diet: forget restriction, replace with balance!. <i>European Heart Journal</i> , 2020, 41, 1058-1058.	1.0	5
214	Inclisiran – New hope in the management of lipid disorders?. <i>Journal of Clinical Lipidology</i> , 2020, 14, 16-27.	0.6	80
215	Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 300.	3.0	104
216	Evolving concepts on the management of dyslipidaemia. <i>Acta Clinica Belgica</i> , 2020, 75, 80-90.	0.5	3

#	ARTICLE	IF	CITATIONS
217	EQ-5D in coronary patients: what are they suffering from? Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry. <i>Quality of Life Research</i> , 2020, 29, 1037-1046.	1.5	8
218	Effect of Dietary Insulinemia on All-Cause and Cause-Specific Mortality: Results From a Cohort Study. <i>Journal of the American College of Nutrition</i> , 2020, 39, 407-413.	1.1	8
219	Effect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies. <i>Angiology</i> , 2020, 71, 217-225.	0.8	5
220	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. <i>Metabolites</i> , 2020, 10, 392.	1.3	34
221	Lipid levels, atrial fibrillation and the impact of age: Results from the LIPIDOGram2015 study. <i>Atherosclerosis</i> , 2020, 312, 16-22.	0.4	25
222	Pathophysiology of Cardiovascular Complications in COVID-19. <i>Frontiers in Physiology</i> , 2020, 11, 575600.	1.3	33
223	We are infected with the new, mutated virus UO-COVID-19. <i>Archives of Medical Science</i> , 2020, 17, 1706-1715.	0.4	12
224	Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154375.	1.5	40
225	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2020, 14, 649-659.e6.	0.6	70
226	Telemedicine Across the Globe-Position Paper From the COVID-19 Pandemic Health System Resilience PROGRAM (REPROGRAM) International Consortium (Part 1). <i>Frontiers in Public Health</i> , 2020, 8, 556720.	1.3	162
227	LDL-C: lower is better for longer—even at low risk. <i>BMC Medicine</i> , 2020, 18, 320.	2.3	78
228	Quality of life in heart failure patients undergoing hybrid comprehensive telerehabilitation versus usual care—results of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomized Clinical Trial. <i>Archives of Medical Science</i> , 2020, 17, 1599-1612.	0.4	10
229	Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon?. <i>Biochimie</i> , 2020, 177, 50-52.	1.3	9
230	Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222.	6.3	7,664
231	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	6.3	3,928
232	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	6.3	890
233	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159.	6.3	335
234	Glucose-6-phosphate dehydrogenase deficiency and SARS-CoV-2 mortality: Is there a link and what should we do?. <i>Clinical Biochemistry</i> , 2020, 86, 31-33.	0.8	6

#	ARTICLE	IF	CITATIONS
235	An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 1199-1205.	1.5	10
236	May Measurement Month 2018: an analysis of blood pressure screening campaign results from Poland. European Heart Journal Supplements, 2020, 22, H108-H111.	0.0	4
237	“Apple does not fall far from the tree” subclinical atherosclerosis in children with familial hypercholesterolemia. Lipids in Health and Disease, 2020, 19, 169.	1.2	6
238	EFFICACY AND SAFETY OF ALIROCLUMAB IN A REAL-LIFE SETTING IN PATIENTS WITH OR WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA: THE ODYSSEY APPRISE STUDY. Journal of the American College of Cardiology, 2020, 75, 1958.	1.2	0
239	Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis. PLoS Medicine, 2020, 17, e1003121.	3.9	64
240	Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID-19: Shoot the messenger!. Journal of Cellular and Molecular Medicine, 2020, 24, 10267-10269.	1.6	7
241	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiology, 2020, 5, 1124.	3.0	128
242	Designing Futuristic Telemedicine Using Artificial Intelligence and Robotics in the COVID-19 Era. Frontiers in Public Health, 2020, 8, 556789.	1.3	68
243	Statins and C-reactive protein: in silico evidence on direct interaction. Archives of Medical Science, 2020, 16, 1432-1439.	0.4	44
244	Remote Monitoring of Cardiac Implantable Electronic Devices in Patients Undergoing Hybrid Comprehensive Telerehabilitation in Comparison to the Usual Care. Subanalysis from Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomised Clinical Trial. Journal of Clinical Medicine, 2020, 9, 3729.	1.0	8
245	Particulate matter pollution and the COVID-19 outbreak: results from Italian regions and provinces. Archives of Medical Science, 2020, 16, 985-992.	0.4	64
246	Adverse Impact of Desulfovibrio spp. and Beneficial Role of Anaerostipes spp. on Renal Function: Insights from a Mendelian Randomization Analysis. Nutrients, 2020, 12, 2216.	1.7	21
247	Pathophysiological mechanisms of statin-associated myopathies: possible role of the ubiquitin-proteasome system. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1177-1186.	2.9	14
248	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000-17. The Lancet Global Health, 2020, 8, e1038-e1060.	2.9	23
249	Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. Metabolites, 2020, 10, 428.	1.3	17
250	Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey. Archives of Medical Science, 2020, 16, 1279-1287.	0.4	11
251	Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study. Injury Prevention, 2020, 26, i125-i153.	1.2	44
252	CETP inhibition in the REVEAL trial: could we aim higher?. Archives of Medical Science, 2020, 16, 1229-1230.	0.4	1

#	ARTICLE	IF	CITATIONS
253	The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia. <i>Current Atherosclerosis Reports</i> , 2020, 22, 67.	2.0	15
254	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1250-1284.	6.3	330
255	Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia). <i>Archives of Medical Science</i> , 2020, 16, 993-1003.	0.4	20
256	Monounsaturated Fatty Acid Levels May Not Affect Cardiovascular Events: Results From a Mendelian Randomization Analysis. <i>Frontiers in Nutrition</i> , 2020, 7, 123.	1.6	12
257	Telemedicine as the New Outpatient Clinic Gone Digital: Position Paper From the Pandemic Health System REsilience PROGRAM (REPROGRAM) International Consortium (Part 2). <i>Frontiers in Public Health</i> , 2020, 8, 410.	1.3	111
258	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17. <i>The Lancet Global Health</i> , 2020, 8, e1162-e1185.	2.9	91
259	The global distribution of lymphatic filariasis, 2000–18: a geospatial analysis. <i>The Lancet Global Health</i> , 2020, 8, e1186-e1194.	2.9	98
260	A Greater Flavonoid Intake Is Associated with Lower Total and Cause-Specific Mortality: A Meta-Analysis of Cohort Studies. <i>Nutrients</i> , 2020, 12, 2350.	1.7	13
261	Comparative effect of nutraceuticals on lipid profile: a protocol for systematic review and network meta-analysis. <i>BMJ Open</i> , 2020, 10, e032755.	0.8	5
262	Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i96-i114.	1.2	103
263	Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2982-3021.	1.2	4,468
264	Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants. <i>Lancet, The</i> , 2020, 396, 1511-1524.	6.3	219
265	Unrealistic Optimism in the Time of Coronavirus Pandemic: May It Help to Kill, If So—Whom: Disease or the Person?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1464.	1.0	70
266	Potential effects of curcumin in the treatment of COVID-19 infection. <i>Phytotherapy Research</i> , 2020, 34, 2911-2920.	2.8	236
267	Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. <i>Pharmacological Research</i> , 2020, 158, 104891.	3.1	62
268	Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. <i>Archives of Medical Science</i> , 2020, 16, 485-489.	0.4	70
269	Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2. <i>Archives of Medical Science</i> , 2020, 16, 519-521.	0.4	14
270	Statins and the COVID-19 main protease: in silico evidence on direct interaction. <i>Archives of Medical Science</i> , 2020, 16, 490-496.	0.4	218

#	ARTICLE	IF	CITATIONS
271	Epigenetic control of atherosclerosis via DNA methylation: A new therapeutic target?. <i>Life Sciences</i> , 2020, 253, 117682.	2.0	9
272	Global trends of hand and wrist trauma: a systematic analysis of fracture and digit amputation using the Global Burden of Disease 2017 Study. <i>Injury Prevention</i> , 2020, 26, i115-i124.	1.2	51
273	Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?. <i>Archives of Medical Research</i> , 2020, 51, 733-735.	1.5	47
274	Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. <i>Drug Discovery Today</i> , 2020, 25, 1487-1501.	3.2	2
275	Lipid profile and left ventricular geometry pattern in obese children. <i>Lipids in Health and Disease</i> , 2020, 19, 109.	1.2	12
276	Cholesterol in Relation to COVID-19: Should We Care about It?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1909.	1.0	110
277	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000â€“17: analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2020, 395, 1779-1801.	6.3	72
278	RELATIONSHIP BETWEEN LOW-DENSITY LIPOPROTEIN CHOLESTEROL, LIPID LOWERING AGENTS AND THE RISK OF STROKE: A META-ANALYSIS OF OBSERVATIONAL STUDIES AND RANDOMIZED CONTROLLED TRIALS. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2080.	1.2	3
279	The burden of unintentional drowning: global, regional and national estimates of mortality from the Global Burden of Disease 2017 Study. <i>Injury Prevention</i> , 2020, 26, i83-i95.	1.2	109
280	Cytokine Storm in COVID-19â€™ Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. <i>Frontiers in Immunology</i> , 2020, 11, 1648.	2.2	370
281	The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 561-581.	3.7	69
282	Potato consumption is associated with total and cause-specific mortality: a population-based cohort study and pooling of prospective studies with 98,569 participants. <i>Archives of Medical Science</i> , 2020, 16, 260-272.	0.4	9
283	2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders. <i>Archives of Medical Science</i> , 2020, 16, 237-252.	0.4	37
284	SLEEP DURATION MAY NOT HAVE ANY EFFECT ON THE RISK OF STROKE: INSIGHTS FROM MENDELIAN RANDOMIZATION AND PROSPECTIVE COHORT STUDIES. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2038.	1.2	3
285	Cardioprotective properties of leptin in patients with excessive body mass. <i>Irish Journal of Medical Science</i> , 2020, 189, 1259-1265.	0.8	6
286	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , 2020, 33, 155-179.	2.1	31
287	Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. <i>Journal of the American Heart Association</i> , 2020, 9, e014129.	1.6	25
288	Changes in disease burden in Poland between 1990â€“2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017. <i>PLoS ONE</i> , 2020, 15, e0226766.	1.1	33

#	ARTICLE	IF	CITATIONS
289	Statins and autoimmunity: State-of-the-art. , 2020, 214, 107614.		29
290	Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. Thrombosis Research, 2020, 195, 128-135.	0.8	3
291	Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations. Journal of Clinical Medicine, 2020, 9, 170.	1.0	9
292	A high consumption of tomato and lycopene is associated with a lower risk of cancer mortality: results from a multi-ethnic cohort. Public Health Nutrition, 2020, 23, 1569-1575.	1.1	23
293	Where are the Recommendations on Healthy Lifestyle and Cardiovascular Disease Prevention for Pregnant Women?. Journal of the American Heart Association, 2020, 9, e016052.	1.6	6
294	Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Diseaseâ€”A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. Diabetes Care, 2020, 43, 726-733.	4.3	46
295	Statin therapy in athletes and patients performing regular intense exercise â€” Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	3.1	17
296	Pharmacological management of malignant hypertension. Expert Opinion on Pharmacotherapy, 2020, 21, 1189-1192.	0.9	4
297	Treating mild hypertension in young adults: is pharmacotherapy necessary?. Expert Opinion on Pharmacotherapy, 2020, 21, 1115-1118.	0.9	1
298	Global, regional, and national burden of chronic kidney disease, 1990â€”2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	6.3	2,858
299	Effects of immunisation against PCSK9 in mice bearing melanoma. Archives of Medical Science, 2020, 16, 189-199.	0.4	17
300	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990â€”2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 245-266.	3.7	823
301	Incretins and microRNAs: Interactions and physiological relevance. Pharmacological Research, 2020, 153, 104662.	3.1	11
302	Epidemiology of facial fractures: incidence, prevalence and years lived with disability estimates from the Global Burden of Disease 2017 study. Injury Prevention, 2020, 26, i27-i35.	1.2	67
303	Highâ€”Sensitivity Câ€”Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study. Journal of the American Heart Association, 2020, 9, e013600.	1.6	43
304	Epigenetics in atherosclerosis: key features and therapeutic implications. Expert Opinion on Therapeutic Targets, 2020, 24, 719-721.	1.5	4
305	What do we know about the role of lipoprotein(a) in atherogenesis 57Â”years after its discovery?. Progress in Cardiovascular Diseases, 2020, 63, 219-227.	1.6	35
306	An overview of statin-induced myopathy and perspectives for the future. Expert Opinion on Drug Safety, 2020, 19, 601-615.	1.0	38

#	ARTICLE	IF	CITATIONS
307	Clinical factors related to successful or unsuccessful cardioversion in the Edoxaban versus warfarin in subjects Undergoing cardioversion of Atrial Fibrillation (ENSURE- AF) randomized trial. <i>Journal of Arrhythmia</i> , 2020, 36, 430-438.	0.5	4
308	Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. <i>Lancet, The</i> , 2020, 396, 693-724.	6.3	87
309	Association between rs2107595 HDAC9 gene polymorphism and advanced carotid atherosclerosis in the Slovenian cohort. <i>Lipids in Health and Disease</i> , 2020, 19, 71.	1.2	6
310	Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. <i>Clinical Nutrition</i> , 2020, 39, 3677-3686.	2.3	52
311	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. <i>Nature Medicine</i> , 2020, 26, 750-759.	15.2	47
312	Egg Intake: Getting the Balance Right!. <i>Angiology</i> , 2020, 71, 585-585.	0.8	0
313	The potential role of plant-derived natural products in improving arterial stiffness: A review of dietary intervention studies. <i>Trends in Food Science and Technology</i> , 2020, 99, 426-440.	7.8	42
314	Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go. <i>JAMA Network Open</i> , 2020, 3, e2025675.	2.8	27
315	Post-exercise Hypotension in the Elderly. , 2020, , 45-56.		1
316	Vitamin D and SAMS. <i>Contemporary Cardiology</i> , 2020, , 121-128.	0.0	3
317	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. <i>Atherosclerosis Supplements</i> , 2020, 42, e15-e24.	1.2	18
318	Clinical approach to the inflammatory etiology of cardiovascular diseases. <i>Pharmacological Research</i> , 2020, 159, 104916.	3.1	56
319	The Role of Adipokines in the Development of Arterial Stiffness and Hypertension. <i>Angiology</i> , 2020, 71, 754-761.	0.8	15
320	Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications. <i>Current Medicinal Chemistry</i> , 2020, 27, 1021-1040.	1.2	21
321	New trends in the pharmacological intervention of PPARs in obesity: Role of natural and synthetic compounds_. <i>Current Medicinal Chemistry</i> , 2020, 28, 4004-4022.	1.2	2
322	185-OR: Efficacy and Safety of Bempedoic Acid in Patients with Diabetes, Prediabetes, and Normoglycemia: Analysis of Pooled Patient-Level Data from Four Phase 3 Clinical Trials. <i>Diabetes</i> , 2020, 69, .	0.3	1
323	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies. <i>Archives of Medical Science</i> , 2020, 18, 604-616.	0.4	9
324	Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey. <i>Cardiology Journal</i> , 2020, 27, 533-540.	0.5	18

#	ARTICLE	IF	CITATIONS
325	Carotid Sinus Syndrome. , 2020, , 23-34.		0
326	Novel strategies of hypertension management in chronic kidney disease. Archives of Medical Science, 2020, , .	0.4	0
327	Adverse impact of egg consumption on fatty liver is partially explained by cardiometabolic risk factors: A population-based study. Clinical Nutrition, 2020, 39, 3730-3735.	2.3	3
328	The outcomes of hypertension treatment depending on gender in patients over 40 years of age. Przegląd Menopauzalny, 2020, 19, 174-178.	0.6	2
329	Title is missing!. , 2020, 17, e1003121.		0
330	Title is missing!. , 2020, 17, e1003121.		0
331	Title is missing!. , 2020, 17, e1003121.		0
332	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. Cardiovascular Research, 2019, 115, 204-212.	1.8	34
333	Subclinical hypothyroidism and the development of heart failure: an overview of risk and effects on cardiac function. Clinical Research in Cardiology, 2019, 108, 225-233.	1.5	35
334	Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opinion on Pharmacotherapy, 2019, 20, 2007-2017.	0.9	21
335	Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease. Journal of the American College of Nutrition, 2019, 38, 633-639.	1.1	13
336	Resveratrol and cognitive decline: a clinician perspective. Archives of Medical Science, 2019, 15, 936-943.	0.4	41
337	Bacterial infections are associated with cardiovascular disease in Iran: a meta-analysis. Archives of Medical Science, 2019, 15, 902-911.	0.4	13
338	The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals. Atherosclerosis, 2019, 288, 33-41.	0.4	28
339	Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. Journal of Clinical Lipidology, 2019, 13, 634-644.	0.6	32
340	The potential role of inflammation in cryptogenic stroke. Advances in Medical Sciences, 2019, 64, 381-387.	0.9	8
341	Dietary choline is positively related to overall and cause-specific mortality: results from individuals of the National Health and Nutrition Examination Survey and pooling prospective data. British Journal of Nutrition, 2019, 122, 1262-1270.	1.2	18
342	PCSK9 and inflammation: a review of experimental and clinical evidence. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 237-245.	1.4	104

#	ARTICLE	IF	CITATIONS
343	SU87PCSK9 GENETIC VARIANTS, LIFE-LONG LOWERING OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL, AND COGNITIVE ABILITIES. <i>European Neuropsychopharmacology</i> , 2019, 29, S1312.	0.3	0
344	Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. <i>Lipids in Health and Disease</i> , 2019, 18, 188.	1.2	31
345	The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109526.	2.5	15
346	Hybrid comprehensive telerehabilitation in heart failure patients (TELEREH-HF): A randomized, multicenter, prospective, open-label, parallel group controlled trial—Study design and description of the intervention. <i>American Heart Journal</i> , 2019, 217, 148-158.	1.2	38
347	Parenteral systems for statin delivery: a review. <i>Lipids in Health and Disease</i> , 2019, 18, 193.	1.2	21
348	Arterial Stiffness and Indices of Left Ventricular Diastolic Dysfunction in Patients with Embolic Stroke of Undetermined Etiology. <i>Disease Markers</i> , 2019, 2019, 1-10.	0.6	8
349	The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1856.	1.0	27
350	Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units. <i>Journal of Clinical Medicine</i> , 2019, 8, 1742.	1.0	9
351	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <i>Lancet HIV</i> , 2019, 6, e831-e859.	2.1	341
352	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , 2019, 39, e1-e8.	1.2	31
353	The Role of Mesenchymal Stem Cells in Atherosclerosis: Prospects for Therapy via the Modulation of Inflammatory Milieu. <i>Journal of Clinical Medicine</i> , 2019, 8, 1413.	1.0	23
354	Current research in biotechnology: Exploring the biotech forefront. <i>Current Research in Biotechnology</i> , 2019, 1, 34-40.	1.9	17
355	Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the Very Large Database of Lipids Studies 6 and 7. <i>Archives of Medical Science</i> , 2019, 15, 1195-1202.	0.4	16
356	Regulation of cardiac stem cells by microRNAs: State-of-the-art. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109447.	2.5	7
357	Association of Empirical Dietary Atherogenic Indices with All-Cause and Cause-Specific Mortality in a Multi-Ethnic Adult Population of the United States. <i>Nutrients</i> , 2019, 11, 2323.	1.7	14
358	Worldwide Dyslipidemia Guidelines. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	17
359	A systematic review and meta-analysis of clinical trials investigating the effects of flaxseed supplementation on plasma C-reactive protein concentrations. <i>Archives of Medical Science</i> , 2019, 15, 12-22.	0.4	10
360	Effect of Statin Therapy on Arterial Wall Inflammation Based on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis of Interventional Studies. <i>Journal of Clinical Medicine</i> , 2019, 8, 118.	1.0	48

#	ARTICLE	IF	CITATIONS
361	Egg Consumption and Risk of Total and Cause-Specific Mortality: An Individual-Based Cohort Study and Pooling Prospective Studies on Behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. <i>Journal of the American College of Nutrition</i> , 2019, 38, 552-563.	1.1	31
362	Do we know more about hypertension in Poland after the May Measurement Month 2017? Europe. <i>European Heart Journal Supplements</i> , 2019, 21, D97-D100.	0.0	6
363	Effects of immunization against PCSK9 in an experimental model of breast cancer. <i>Archives of Medical Science</i> , 2019, 15, 570-579.	0.4	37
364	Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer. <i>Archives of Medical Science</i> , 2019, 15, 559-569.	0.4	29
365	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , 2019, 285, 135-146.	0.4	227
366	Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies. <i>European Heart Journal</i> , 2019, 40, 2870-2879.	1.0	103
367	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. <i>European Heart Journal</i> , 2019, 40, 2006-2017.	1.0	193
368	Beneficial effects of pre-stroke statins use in cardioembolic stroke patients with atrial fibrillation: a hospital-based retrospective analysis. <i>Archives of Medical Science</i> , 2019, 15, 385-392.	0.4	11
369	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019, 143, 1-16.	3.1	90
370	Novel therapeutic strategies for stroke: The role of autophagy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 182-199.	2.7	40
371	A review of gene- and cell-based therapies for familial hypercholesterolemia. <i>Pharmacological Research</i> , 2019, 143, 119-132.	3.1	24
372	Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 439-458.	4.9	2,005
373	Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 459-480.	4.9	2,625
374	Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. <i>Lipids in Health and Disease</i> , 2019, 18, 88.	1.2	26
375	Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. <i>Journal of the American Heart Association</i> , 2019, 8, e011662.	1.6	292
376	Antitumor effects of curcumin: A lipid perspective. <i>Journal of Cellular Physiology</i> , 2019, 234, 14743-14758.	2.0	39
377	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 824-835.	0.8	558
378	Associations between the lipid profile and the development of hypertension in young individuals – the preliminary study. <i>Archives of Medical Science</i> , 2019, 18, 25-35.	0.4	4

#	ARTICLE	IF	CITATIONS
379	Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. <i>Nutrients</i> , 2019, 11, 2580.	1.7	39
380	Ca ²⁺ Flux: Searching for a Role in Efferocytosis of Apoptotic Cells in Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 2047.	1.0	16
381	Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. <i>Journal of Clinical Medicine</i> , 2019, 8, 2051.	1.0	60
382	Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!. <i>Archives of Medical Science</i> , 2019, 15, 1357-1364.	0.4	31
383	Pulse wave velocity as a measure of arterial stiffness in patients with familial hypercholesterolemia: a systematic review and meta-analysis. <i>Archives of Medical Science</i> , 2019, 15, 1365-1374.	0.4	18
384	Association of ideal cardiovascular health metrics with serum uric acid, inflammation and atherogenic index of plasma: A population-based survey. <i>Atherosclerosis</i> , 2019, 284, 44-49.	0.4	24
385	Consumption of dairy product and its association with total and cause-specific mortality – A population-based cohort study and meta-analysis. <i>Clinical Nutrition</i> , 2019, 38, 2833-2845.	2.3	50
386	Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent. <i>Journal of Nutritional Biochemistry</i> , 2019, 66, 1-16.	1.9	112
387	Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF). <i>American Journal of Cardiology</i> , 2019, 123, 592-597.	0.7	10
388	Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults. <i>International Journal of Cardiology</i> , 2019, 276, 242-247.	0.8	30
389	Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic survey. <i>Atherosclerosis</i> , 2019, 284, 129-135.	0.4	12
390	High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 12-24.	3.1	49
391	What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?. <i>Cardiovascular Research</i> , 2019, 115, e26-e31.	1.8	46
392	Dietary natural products as emerging lipoprotein(a)-lowering agents. <i>Journal of Cellular Physiology</i> , 2019, 234, 12581-12594.	2.0	29
393	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. <i>European Journal of Epidemiology</i> , 2019, 34, 247-258.	2.5	22
394	A higher ratio of refined grain to whole grain is associated with a greater likelihood of chronic kidney disease: a population-based study. <i>British Journal of Nutrition</i> , 2019, 121, 1294-1302.	1.2	12
395	A higher flavonoid intake is associated with less likelihood of nonalcoholic fatty liver disease: results from a multiethnic study. <i>Journal of Nutritional Biochemistry</i> , 2019, 65, 66-71.	1.9	30
396	Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes – Data from the TERCET registry with 19,287 patients. <i>Pharmacological Research</i> , 2019, 139, 460-466.	3.1	28

#	ARTICLE	IF	CITATIONS
397	Role of Geriatric Syndromes in the Management of Atrial Fibrillation in Older Adults: A Narrative Review. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 123-130.	1.2	9
398	Application of nanotechnology to improve the therapeutic benefits of statins. <i>Drug Discovery Today</i> , 2019, 24, 567-574.	3.2	31
399	Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 1178-1187.	5.4	52
400	Lifestyle behaviour and risk factor control in coronary patients: Belgian results from the cross-sectional EUROASPIRE surveys. <i>Acta Cardiologica</i> , 2019, 74, 21-27.	0.3	3
401	Cytisine - From the Past to the Future. <i>Current Pharmaceutical Design</i> , 2019, 24, 4413-4423.	0.9	13
402	Cholesterol Subfraction Analysis in Patients with Acute Coronary Syndrome. <i>Current Vascular Pharmacology</i> , 2019, 17, 365-375.	0.8	10
403	Established and potential echocardiographic markers of embolism and their therapeutic implications in patients with ischemic stroke. <i>Cardiology Journal</i> , 2019, 26, 438-450.	0.5	6
404	Effect of atorvastatin on delirium status of patients in the intensive care unit: a randomized controlled trial. <i>Archives of Medical Science</i> , 2019, 17, 1423-1428.	0.4	35
405	Dietary inflammatory index and cardiometabolic risk in US adults. <i>Atherosclerosis</i> , 2018, 276, 23-27.	0.4	78
406	Statin Intolerance. <i>Cardiology Clinics</i> , 2018, 36, 225-231.	0.9	36
407	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1397-1408.	2.6	83
408	Association between plasma trans fatty acids concentrations and leucocyte telomere length in US adults. <i>European Journal of Clinical Nutrition</i> , 2018, 72, 581-586.	1.3	16
409	The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland. <i>Atherosclerosis</i> , 2018, 270, 132-138.	0.4	23
410	Pro sarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 331-353.	4.0	20
411	Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines. <i>Circulation</i> , 2018, 138, 244-254.	1.6	34
412	The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 427-435.	1.9	37
413	Higher dietary acid load is associated with higher likelihood of peripheral arterial disease among American adults. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 565-569.	1.2	23
414	Resveratrol effect on patients with non-alcoholic fatty liver disease: A matter of dose and treatment length. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1798-1799.	2.2	27

#	ARTICLE	IF	CITATIONS
415	Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995–2015. <i>Lancet, The</i> , 2018, 391, 1799-1829.	6.3	127
416	Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40. <i>Lancet, The</i> , 2018, 391, 1783-1798.	6.3	172
417	Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Drugs</i> , 2018, 78, 453-462.	4.9	64
418	Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Clinical Lipidology</i> , 2018, 12, 801-809.	0.6	19
419	The link between insulin resistance parameters and serum uric acid is mediated by adiposity. <i>Atherosclerosis</i> , 2018, 270, 180-186.	0.4	59
420	Botanicals and phytochemicals active on cognitive decline: The clinical evidence. <i>Pharmacological Research</i> , 2018, 130, 204-212.	3.1	53
421	Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry. <i>Pharmacological Research</i> , 2018, 132, 204-210.	3.1	20
422	Management of Statin Intolerance in 2018: Still More Questions Than Answers. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 157-173.	1.0	130
423	Serum uric acid levels are associated with cardiovascular risk score: A post hoc analysis of the EURIKA study. <i>International Journal of Cardiology</i> , 2018, 253, 167-173.	0.8	47
424	Effect of fibrates on glycemic parameters: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Pharmacological Research</i> , 2018, 132, 232-241.	3.1	25
425	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 119-127.	1.4	17
426	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	1.0	262
427	Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants. <i>International Journal of Epidemiology</i> , 2018, 47, 872-883i.	0.9	65
428	Novel drugs for heart rate control in heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 517-525.	1.7	8
429	Evaluation of a dimeric-cRGD peptide for targeted PET-CT imaging of peripheral angiogenesis in diabetic mice. <i>Scientific Reports</i> , 2018, 8, 5401.	1.6	10
430	Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults. <i>Annals of Medicine</i> , 2018, 50, 1-6.	1.5	63
431	Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 1706-1714.	5.4	18
432	Lipoprotein(a): A missing culprit in the management of athero–thrombosis?. <i>Journal of Cellular Physiology</i> , 2018, 233, 2966-2981.	2.0	61

#	ARTICLE	IF	CITATIONS
433	Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 2549-2556.	5.4	60
434	Telomere Length Is Associated With Cardiometabolic Factors in US Adults. <i>Angiology</i> , 2018, 69, 164-169.	0.8	37
435	PCSK9 and infection: A potentially useful or dangerous association?. <i>Journal of Cellular Physiology</i> , 2018, 233, 2920-2927.	2.0	26
436	MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 224-233.	2.9	27
437	Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 266-270.	1.2	97
438	Effect of soy isoflavone supplementation on plasma lipoprotein(a) concentrations: A meta-analysis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 16-24.	0.6	24
439	HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions. <i>Drug Discovery Today</i> , 2018, 23, 171-180.	3.2	17
440	Effects of coenzyme Q10 supplementation on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2018, 128, 130-136.	3.1	34
441	C-reactive Protein Is Associated With Prevalence of the Metabolic Syndrome, Hypertension, and Diabetes Mellitus in US Adults. <i>Angiology</i> , 2018, 69, 438-442.	0.8	52
442	Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. <i>Medical Oncology</i> , 2018, 35, 4.	1.2	17
443	Association Between Plasma Trans-Fatty Acid Concentrations and Measures of Glucose Homeostasis and Cardiovascular Risk Factors in Adults in NHANES 1999-2000. <i>Angiology</i> , 2018, 69, 630-637.	0.8	7
444	Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 165-170.	1.3	15
445	Bleeding in advanced CKD patients on antithrombotic medication – A critical appraisal. <i>Pharmacological Research</i> , 2018, 129, 535-543.	3.1	16
446	The impact of argan oil on plasma lipids in humans: Systematic review and meta-analysis of randomized controlled trials. <i>Phytotherapy Research</i> , 2018, 32, 377-383.	2.8	11
447	Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. <i>Drugs</i> , 2018, 78, 99-109.	4.9	36
448	Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. <i>BMJ Open</i> , 2018, 8, e021508.	0.8	14
449	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	6.3	716
450	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	6.3	4,989

#	ARTICLE	IF	CITATIONS
451	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	6.3	3,269
452	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	6.3	294
453	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
454	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
455	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	6.3	2,123
456	Inverse association between serum antioxidant levels and inflammatory markers is moderated by adiposity: a report based on a large representative population sample of American adults. <i>British Journal of Nutrition</i> , 2018, 120, 1272-1278.	1.2	14
457	Prevalence of childhood and adolescent overweight and obesity in Asian countries: a systematic review and meta-analysis. <i>Archives of Medical Science</i> , 2018, 14, 1185-1203.	0.4	64
458	Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. <i>New England Journal of Medicine</i> , 2018, 379, 2429-2437.	13.9	959
459	Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2018, 8, 17887.	1.6	48
460	Oxidative Stress in Women Treated with Atosiban for Impending Preterm Birth. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-8.	1.9	9
461	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.4	163
462	The impact of nuts consumption on glucose/insulin homeostasis and inflammation markers mediated by adiposity factors among American adults. <i>Oncotarget</i> , 2018, 9, 31173-31186.	0.8	11
463	MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 967-981.	4.0	48
464	Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1857-1865.	0.9	16
465	Incidence of familial hypercholesterolemia in patients from the tercet registry. <i>Atherosclerosis</i> , 2018, 275, e221.	0.4	1
466	Introducing the "Drucebo"™ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1023-1033.	2.9	84
467	The Yin and Yang of carbon nanomaterials in atherosclerosis. <i>Biotechnology Advances</i> , 2018, 36, 2232-2247.	6.0	43
468	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. <i>Data in Brief</i> , 2018, 21, 1334-1336.	0.5	4

#	ARTICLE	IF	CITATIONS
469	Adiposity mediates the association between whole grain consumption, glucose homeostasis and insulin resistance: findings from the US NHANES. <i>Lipids in Health and Disease</i> , 2018, 17, 219.	1.2	12
470	Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. <i>BMC Medicine</i> , 2018, 16, 158.	2.3	15
471	Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>European Heart Journal</i> , 2018, 39, 3641-3653.	1.0	69
472	Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey. <i>European Heart Journal</i> , 2018, 39, 3635-3640.	1.0	25
473	The optimal time of day for statin administration: a review of current evidence. <i>Current Opinion in Lipidology</i> , 2018, 29, 340-345.	1.2	15
474	Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?. <i>International Urology and Nephrology</i> , 2018, 50, 1633-1642.	0.6	3
475	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
476	PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1123-1132.	0.6	39
477	Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the Edoxaban vs. warfarin in subjects Undergoing cardioversion of atrial fibrillation (ENSURE-AF) study. <i>Europace</i> , 2018, 20, 1936-1943.	0.7	17
478	Modulation of heat shock proteins by statins. <i>Pharmacological Research</i> , 2018, 134, 134-144.	3.1	11
479	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.	1.2	216
480	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. <i>International Journal of Cardiology</i> , 2018, 272, 20-25.	0.8	24
481	Impact of fibrates on circulating cystatin C levels: a systematic review and meta-analysis of clinical trials. <i>Annals of Medicine</i> , 2018, 50, 485-493.	1.5	7
482	Natural approaches in metabolic syndrome management. <i>Archives of Medical Science</i> , 2018, 14, 422-441.	0.4	103
483	Novel Therapeutic Targets for Managing Dyslipidemia. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 733-747.	4.0	31
484	Complications of Diabetes 2017. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-4.	1.0	307
485	Monocyte-to-HDL cholesterol ratio as a prognostic marker in cardiovascular diseases. <i>Journal of Cellular Physiology</i> , 2018, 233, 9237-9246.	2.0	169
486	Hypercholesterolaemia – practical information for non-specialists. <i>Archives of Medical Science</i> , 2018, 1, 1-21.	0.4	39

#	ARTICLE	IF	CITATIONS
487	Link between plasma trans-fatty acid and fatty liver is moderated by adiposity. <i>International Journal of Cardiology</i> , 2018, 272, 316-322.	0.8	16
488	Natural products for targeted therapy in precision medicine. <i>Biotechnology Advances</i> , 2018, 36, 1559-1562.	6.0	8
489	Effect of magnesium supplements on serum C-reactive protein: a systematic review and meta-analysis. <i>Archives of Medical Science</i> , 2018, 14, 707-716.	0.4	51
490	Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. <i>Archives of Medical Science</i> , 2018, 14, 890-909.	0.4	42
491	Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?. <i>Current Heart Failure Reports</i> , 2018, 15, 224-238.	1.3	14
492	Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases. <i>Current Pharmaceutical Design</i> , 2018, 24, 239-258.	0.9	87
493	Serum lipophilic antioxidants levels are associated with leucocyte telomere length among US adults. <i>Lipids in Health and Disease</i> , 2018, 17, 164.	1.2	8
494	Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2018, 17, 21.	2.7	15
495	Effect of statins on toll-like receptors: a new insight to pleiotropic effects. <i>Pharmacological Research</i> , 2018, 135, 230-238.	3.1	100
496	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 392, 1015-1035.	6.3	2,005
497	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	1.0	6,826
498	Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Medicine</i> , 2018, 50, 565-575.	1.5	36
499	Phytol: A review of biomedical activities. <i>Food and Chemical Toxicology</i> , 2018, 121, 82-94.	1.8	198
500	High density lipoprotein cholesterol and cancer: Marker or causative?. <i>Progress in Lipid Research</i> , 2018, 71, 54-69.	5.3	79
501	From meta-analysis to Cochrane reviews. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 441-443.	2.9	3
502	Leptin, cardiovascular diseases and type 2 diabetes mellitus. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1176-1188.	2.8	197
503	Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. <i>Atherosclerosis</i> , 2018, 277, 195-203.	0.4	298
504	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an ‘FCS score’. <i>Atherosclerosis</i> , 2018, 275, 265-272.	0.4	131

#	ARTICLE	IF	CITATIONS
505	Blood pressure and kidney update 2016/2017. Archives of Medical Science, 2018, , .	0.4	0
506	Effect of Metformin on Plasma Fibrinogen Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Current Pharmaceutical Design, 2018, 24, 1034-1040.	0.9	3
507	Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm. Angiology, 2017, 68, 99-108.	0.8	35
508	Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opinion on Investigational Drugs, 2017, 26, 251-259.	1.9	40
509	PCSK9 and diabetes: is there a link?. Drug Discovery Today, 2017, 22, 883-895.	3.2	39
510	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Revista Espanola De Cardiologia (English Ed), 2017, 70, 115.	0.4	77
511	Are two drugs better than one? A review of combination therapies for hypertension. Expert Opinion on Pharmacotherapy, 2017, 18, 377-386.	0.9	17
512	Epidemiology and prevention of cardiovascular disease: Quo vadis?. European Journal of Preventive Cardiology, 2017, 24, 768-772.	0.8	24
513	Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Medicine, 2017, 15, 22.	2.3	65
514	The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review. Lipids in Health and Disease, 2017, 16, 35.	1.2	7
515	Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Cardiovascular Drugs and Therapy, 2017, 31, 197-208.	1.3	22
516	Impact of Statin Therapy on Plasma MMP-3, MMP-9, and TIMP-1 Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Angiology, 2017, 68, 850-862.	0.8	20
517	Systolicâ€“diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study. International Journal of Cardiology, 2017, 235, 11-16.	0.8	26
518	Effects of curcumin on HDL functionality. Pharmacological Research, 2017, 119, 208-218.	3.1	157
519	Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease. Journal of Clinical Lipidology, 2017, 11, 617-623.	0.6	19
520	HDL abnormalities in familial hypercholesterolemia: Focus on biological functions. Progress in Lipid Research, 2017, 67, 16-26.	5.3	51
521	Curcumin: A Naturally Occurring Modulator of Adipokines in Diabetes. Journal of Cellular Biochemistry, 2017, 118, 4170-4182.	1.2	42
522	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. Journal of Clinical Lipidology, 2017, 11, 972-985.e9.	0.6	40

#	ARTICLE	IF	CITATIONS
523	Response letter: Management of statin-induced myopathies: Much demands and still (almost) empty hands!. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 514-515.	2.9	2
524	The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV. <i>Diabetes Care</i> , 2017, 40, 1233-1240.	4.3	83
525	Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor- α concentrations: A systematic review and meta-analysis of controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1458-1464.	1.2	19
526	Statins, haemostatic factors and thrombotic risk. <i>Current Opinion in Cardiology</i> , 2017, 32, 460-466.	0.8	22
527	The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. <i>Drugs</i> , 2017, 77, 1187-1197.	4.9	29
528	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	3.1	21
529	Isolated diastolic hypertension and incident heart failure in community-dwelling older adults: Insights from the Cardiovascular Health Study. <i>International Journal of Cardiology</i> , 2017, 238, 140-143.	0.8	19
530	Regulation of PCSK9 by nutraceuticals. <i>Pharmacological Research</i> , 2017, 120, 157-169.	3.1	89
531	Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. <i>Nutrition Reviews</i> , 2017, 75, 361-373.	2.6	39
532	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1967-1976.	0.4	14
533	EDOxaban Therapy Increases Treatment Satisfaction and Reduces Utilization of Health Care Resources: An Analysis From the EDOxaban Versus Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation (ENSURE-AF) Study. <i>Journal of the American College of Cardiology</i> , 2017, 69, 454.	1.2	0
534	Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1386-1395.	1.2	258
535	Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials. <i>Journal of Clinical Lipidology</i> , 2017, 11, 624-637.	0.6	30
536	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1713-1722.	13.9	4,179
537	A nutraceutical approach (Armolidip Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. <i>Atherosclerosis Supplements</i> , 2017, 24, 1-15.	1.2	83
538	PCSK9 inhibitors in sepsis: a new potential indication?. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 137-139.	1.9	20
539	Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?. <i>International Urology and Nephrology</i> , 2017, 49, 155-164.	0.6	17
540	The assessment of selected markers of cardiac dysfunction in the analysis of cardiovascular risk in dialysis patients. <i>Atherosclerosis</i> , 2017, 263, e273.	0.4	0

#	ARTICLE	IF	CITATIONS
541	Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. <i>Lancet, The</i> , 2017, 390, 2627-2642.	6.3	5,010
542	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	2.6	238
543	The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. <i>Atherosclerosis</i> , 2017, 265, 275-282.	0.4	144
544	Lipids profile and efficacy of treatment of dyslipidemia in primary care in Poland. Results of lipidogram 5 years study (2004-2010). <i>Atherosclerosis</i> , 2017, 263, e187.	0.4	1
545	Usefulness of atherogenic dyslipidemia index to assess the cardiovascular risk of primary care patients - Results from lipidogram 2004 and lipidogram 2006 studies. <i>Atherosclerosis</i> , 2017, 263, e265.	0.4	0
546	The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction. <i>Scientific Reports</i> , 2017, 7, 8974.	1.6	12
547	Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents. <i>Current Opinion in Lipidology</i> , 2017, 28, 495-501.	1.2	31
548	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 419-431.	1.3	45
549	The relationship of renal function to outcome: A post hoc analysis from the Edoxaban versus warfarin in subjects Undergoing cardioversion of Atrial Fibrillation (ENSURE-AF) study. <i>American Heart Journal</i> , 2017, 193, 16-22.	1.2	9
550	Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials. <i>Pharmacological Research</i> , 2017, 124, 64-73.	3.1	4
551	The effects of cinnamon supplementation on blood lipid concentrations: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1393-1406.	0.6	60
552	Definition and Characteristics of Hypertension Associated with Chronic Kidney Disease: Epidemiological Data. , 2017, , 13-23.		1
553	HDL functionality in type 1 diabetes. <i>Atherosclerosis</i> , 2017, 267, 99-109.	0.4	50
554	Synthesis, Chemical Characterization and Multiscale Biological Evaluation of a Dimeric-cRGD Peptide for Targeted Imaging of $\alpha_5\beta_3$ Integrin Activity. <i>Scientific Reports</i> , 2017, 7, 3185.	1.6	18
555	Blood Pressure, Antihypertensive Polypharmacy, Frailty, and Risk for Serious Fall Injuries Among Older Treated Adults With Hypertension. <i>Hypertension</i> , 2017, 70, 259-266.	1.3	102
556	Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 160.	0.7	80
557	Accuracy of low-density lipoprotein cholesterol estimation at very low levels. <i>BMC Medicine</i> , 2017, 15, 83.	2.3	38
558	Curcumin: An effective adjunct in patients with statin-associated muscle symptoms?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 19-24.	2.9	50

#	ARTICLE	IF	CITATIONS
559	Novel approaches toward the generation of bioscaffolds as a potential therapy in cardiovascular tissue engineering. <i>International Journal of Cardiology</i> , 2017, 228, 319-326.	0.8	24
560	Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19A·1 million participants. <i>Lancet, The</i> , 2017, 389, 37-55.	6.3	1,667
561	Intensive LDL-cholesterol lowering therapy and neurocognitive function. , 2017, 170, 181-191.		55
562	Regular exercise behaviour and intention and symptoms of anxiety and depression in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 84-91.	0.8	20
563	Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?. <i>Drug Discovery Today</i> , 2017, 22, 85-96.	3.2	64
564	One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper. <i>Acta Cardiologica</i> , 2017, 72, 19-27.	0.3	3
565	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1290-1301.	1.2	162
566	Editorial: Natural Products as the Integral Part of the Therapy?. <i>Current Pharmaceutical Design</i> , 2017, 23, 2411-2413.	0.9	5
567	Physical Exercise and DNA Injury. <i>Advances in Clinical Chemistry</i> , 2017, 81, 193-230.	1.8	13
568	Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1248.	1.8	1
569	Vitamin D deficiency and non-lipid biomarkers of cardiovascular risk. <i>Archives of Medical Science</i> , 2017, 4, 732-737.	0.4	48
570	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.	0.4	206
571	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. <i>Archives of Medical Science</i> , 2017, 1, 1-45.	0.4	70
572	The association of telomere length and serum 25-hydroxyvitamin D levels in US adults: the National Health and Nutrition Examination Survey. <i>Archives of Medical Science</i> , 2017, 1, 61-65.	0.4	81
573	Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans. <i>Lipids in Health and Disease</i> , 2017, 16, 192.	1.2	42
574	Dietary patterns, plasma vitamins and Trans fatty acids are associated with peripheral artery disease. <i>Lipids in Health and Disease</i> , 2017, 16, 254.	1.2	26
575	The role of nutraceuticals in the prevention of cardiovascular disease. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 67, S21-S31.	0.7	81
576	Association between telomere length and complete blood count in US adults. <i>Archives of Medical Science</i> , 2017, 3, 601-605.	0.4	30

#	ARTICLE	IF	CITATIONS
577	Hypertension - Current Natural Strategies to Lower Blood Pressure. <i>Current Pharmaceutical Design</i> , 2017, 23, 2453-2461.	0.9	9
578	Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9. <i>Journal of Thoracic Disease</i> , 2017, 9, E78-E82.	0.6	32
579	Telomere attrition, kidney function, and prevalent chronic kidney disease in the United States. <i>Oncotarget</i> , 2017, 8, 80175-80181.	0.8	34
580	Mineral and vitamins consumption is associated with longer telomeres among US adults. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 87-90.	0.3	39
581	PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk. <i>Current Pharmaceutical Design</i> , 2017, 23, 894-902.	0.9	15
582	The Use of Plant Sterols and Stanols as Lipid-Lowering Agents in Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2017, 23, 2488-2495.	0.9	21
583	Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. <i>Current Pharmaceutical Design</i> , 2017, 23, 2496-2503.	0.9	31
584	Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?. <i>Current Pharmaceutical Design</i> , 2017, 23, 3024-3033.	0.9	4
585	High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , 2017, 15, 144-151.	0.8	12
586	Statins and atrial fibrillation - mini - review on recent evidence. <i>Heart Beat Journal</i> , 2017, 1, 43-46.	0.2	1
587	ScreenPro FH - Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe: Basic Epidemiology. <i>Vnitřní Lekarství</i> , 2017, 63, 25-30.	0.1	10
588	ScreenPro FH - Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe: Rationale and Design. <i>Vnitřní Lekarství</i> , 2017, 63, 43-48.	0.1	5
589	Wytyczne PTL/KLRwP/PTK dotyczą...ce postępowania w zaburzeniach lipidowych dla lekarzy rodzinnych 2016. <i>Kardiologia Polska</i> , 2017, 74, 127-168.	0.3	1
590	ScreenPro FH - Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe: Basic Epidemiology. <i>Vnitřní Lekarství</i> , 2017, 63, 25-30.	0.1	5
591	Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?. <i>Current Vascular Pharmacology</i> , 2016, 14, 321-322.	0.8	4
592	Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients. <i>Archives of Medical Science</i> , 2016, 4, 844-849.	0.4	20
593	Complications of Diabetes 2016. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-3.	1.0	164
594	Evaluation of medical and psychological parameters of quality of life in supraventricular tachyarrhythmia children. A comparison with healthy children. <i>Archives of Medical Science</i> , 2016, 5, 1052-1063.	0.4	2

#	ARTICLE	IF	CITATIONS
595	Molecular mechanisms of statin intolerance. Archives of Medical Science, 2016, 3, 645-658.	0.4	58
596	The impact of statin therapy on plasma levels of von Willebrand factor antigen. Thrombosis and Haemostasis, 2016, 115, 520-532.	1.8	138
597	Exosomes as nanocarriers for siRNA delivery: paradigms and challenges. Archives of Medical Science, 2016, 6, 1324-1326.	0.4	41
598	IMPROVE-IT. Current Opinion in Cardiology, 2016, 31, 426-433.	0.8	16
599	Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT. Journal of Hypertension, 2016, 34, 393-396.	0.3	26
600	Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Scientific Reports, 2016, 6, 19188.	1.6	55
601	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90
602	Effects of pentoxifylline on inflammatory markers and blood pressure. Journal of Hypertension, 2016, 34, 2318-2329.	0.3	31
603	Time-saving screening for diabetes in patients with coronary artery disease: a report from EUROASPIRE IV. BMJ Open, 2016, 6, e013835.	0.8	6
604	Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2016, 107, 360-371.	3.1	61
605	Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study. International Journal of Cardiology, 2016, 218, 83-88.	0.8	76
606	Lipid-modifying effects of nutraceuticals: An evidence-based approach. Nutrition, 2016, 32, 1179-1192.	1.1	157
607	Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. Lipids in Health and Disease, 2016, 15, 22.	1.2	25
608	Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys. European Journal of Preventive Cardiology, 2016, 23, 1618-1627.	0.8	19
609	Bioresorbable scaffold "A magic bullet for the treatment of coronary artery disease?". International Journal of Cardiology, 2016, 215, 47-59.	0.8	24
610	Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases "Some answers and still many questions. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 370-378.	2.7	41
611	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis, 2016, 253, 281-344.	0.4	1,189
612	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology, 2016, 225, 184-196.	0.8	155

#	ARTICLE	IF	CITATIONS
613	A systematic review and meta-analysis comparing the effects of statins and fibrates on plasma lipoprotein(a) levels. <i>Atherosclerosis</i> , 2016, 252, e124.	0.4	0
614	Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2049-2056.	0.9	13
615	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. <i>Atherosclerosis</i> , 2016, 253, 194-208.	0.4	142
616	Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies. <i>International Journal of Cardiology</i> , 2016, 221, 1073-1080.	0.8	33
617	Discussion around statin discontinuation in older adults and patients with wasting diseases. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 396-399.	2.9	39
618	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	1.0	2,393
619	Polypills for the prevention of Cardiovascular diseases. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1255-1264.	1.9	17
620	Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 2007-2018.	0.8	153
621	Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	207
622	Can the effects of gender, menopause and ageing on lipid levels be differentiated?. <i>Clinical Endocrinology</i> , 2016, 85, 694-695.	1.2	2
623	Complex relationship of obesity and obesity paradox in heart failure – higher risk of developing heart failure and better outcomes in established heart failure. <i>Annals of Medicine</i> , 2016, 48, 603-613.	1.5	31
624	D-003 (Saccharum officinarum): The forgotten lipid-lowering agent. <i>Pharmacological Research</i> , 2016, 114, 42-46.	3.1	5
625	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016, 6, 30060.	1.6	25
626	Do psychosocial job resources buffer the relation between physical work demands and coronary heart disease? A prospective study among men. <i>International Archives of Occupational and Environmental Health</i> , 2016, 89, 1299-1307.	1.1	20
627	What is the association of lipid levels and incident stroke?. <i>International Journal of Cardiology</i> , 2016, 220, 890-894.	0.8	43
628	Lipoprotein (a) – “We Know So Much Yet Still Have Much to Learn”. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	31
629	Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 335-345.	1.6	155
630	Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. <i>BMC Medicine</i> , 2016, 14, 4.	2.3	68

#	ARTICLE	IF	CITATIONS
631	Expert opinion: the therapeutic challenges faced by statin intolerance. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1497-1507.	0.9	43
632	A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. <i>Pharmacological Research</i> , 2016, 111, 343-356.	3.1	19
633	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	0.8	683
634	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 636-648.	0.8	772
635	Healthy lifestyle factors and incident heart disease and mortality in candidates for primary prevention with statin therapy. <i>International Journal of Cardiology</i> , 2016, 207, 196-202.	0.8	44
636	Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies. <i>Circulation</i> , 2016, 133, 256-264.	1.6	80
637	Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients. <i>Angiology</i> , 2016, 67, 854-859.	0.8	24
638	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 103, 236-252.	3.1	60
639	The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. <i>International Journal of Cardiology</i> , 2016, 209, 284-290.	0.8	77
640	Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 369-380.	0.9	43
641	A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations. <i>Clinical Nutrition</i> , 2016, 35, 842-851.	2.3	98
642	Effect of garlic on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled clinical trials. <i>Nutrition</i> , 2016, 32, 33-40.	1.1	46
643	Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial. <i>Clinical Nutrition</i> , 2016, 35, 615-625.	2.3	78
644	The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , 2016, 14, 260-265.	0.8	11
645	Aortic valve stenosis: what do people know? A heart valve disease awareness survey of over 8,800 people aged 60 or over. <i>EuroIntervention</i> , 2016, 12, 883-889.	1.4	32
646	Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. <i>Kardiologia Polska</i> , 2016, 74, 213-223.	0.3	37
647	Vitamin D deficiency and metabolic syndrome: any link with statin intolerance and adipokines dysregulation?. <i>Clinical Lipidology</i> , 2016, 11, 23-24.	0.4	1
648	Lipids, blood pressure and kidney update 2015. <i>Lipids in Health and Disease</i> , 2015, 14, 167.	1.2	49

#	ARTICLE	IF	CITATIONS
649	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. <i>BMC Medicine</i> , 2015, 13, 229.	2.3	169
650	Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension. <i>Scientific Reports</i> , 2015, 5, 8916.	1.6	27
651	A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. <i>Scientific Reports</i> , 2015, 5, 9902.	1.6	133
652	Association between statin use and plasma D-dimer levels. <i>Thrombosis and Haemostasis</i> , 2015, 114, 546-557.	1.8	127
653	Effect of sour tea (<i>Hibiscus sabdariffa</i> L.) on arterial hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1119-1127.	0.3	102
654	Letter to the Editor Dysfunctional high-density lipoprotein: not only quantity but first of all quality?. <i>Archives of Medical Science</i> , 2015, 1, 230-231.	0.4	7
655	The influence of hypoxic physical activity on cfDNA as a new marker of vascular inflammation. <i>Archives of Medical Science</i> , 2015, 6, 1156-1163.	0.4	24
656	The Relation of Ambulatory Heart Rate with All-Cause Mortality among Middle-Aged Men: A Prospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0121729.	1.1	23
657	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.4	311
658	Systematic review/Meta-analysis Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials. <i>Archives of Medical Science</i> , 2015, 2, 253-266.	0.4	72
659	Complications of Diabetes. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-5.	1.0	83
660	Renalase is Removed by Kidneys and During Dialysis – Excess Related to CKD Complications?. <i>Current Vascular Pharmacology</i> , 2015, 13, 134-140.	0.8	8
661	Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	1.0	1,024
662	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. <i>Atherosclerosis</i> , 2015, 241, 433-442.	0.4	139
663	Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. <i>Atherosclerosis</i> , 2015, 241, 169-175.	0.4	133
664	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015, 14, 133.	2.7	101
665	Impact of anemia treatment with methoxy polyethylene glycol-epoetin beta on polymorphonuclear cells apoptosis in predialysis patients with chronic kidney disease. <i>Pharmacological Reports</i> , 2015, 67, 842-845.	1.5	3
666	Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV – a survey from the European Society of Cardiology. <i>European Heart Journal</i> , 2015, 36, 1171-1177.	1.0	81

#	ARTICLE	IF	CITATIONS
667	Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Functional Foods</i> , 2015, 18, 898-909.	1.6	182
668	Red blood cell transfusion is a determinant of neurological complications after cardiac surgery. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015, 20, 166-171.	0.5	32
669	Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 603-610.	1.9	18
670	Effects of Coenzyme Q10 on Statin-Induced Myopathy. <i>Mayo Clinic Proceedings</i> , 2015, 90, 24-34.	1.4	168
671	Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1212-1219.	0.8	33
672	Effects of supplementation with green tea catechins on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Nutrition</i> , 2015, 31, 1061-1071.	1.1	45
673	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. <i>Atherosclerosis</i> , 2015, 241, e8.	0.4	0
674	Markers of increased cardiovascular risk in elderly patients with chronic kidney disease: A preliminary study. <i>Atherosclerosis</i> , 2015, 241, e184.	0.4	0
675	Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials. <i>Atherosclerosis</i> , 2015, 241, e189-e190.	0.4	1
676	A systematic review and meta-analysis of the impact of spirulina supplementation on plasma lipid concentrations. <i>Atherosclerosis</i> , 2015, 241, e191.	0.4	2
677	Strength-endurance training may promote pro-atherogenic changes in lipoprotein profile of adolescent rowers. <i>Atherosclerosis</i> , 2015, 241, e186-e187.	0.4	1
678	Effect of sour tea (<i>Hibiscus sabdariffa</i> L.) on arterial hypertension: A systematic review and meta-analysis of randomized controlled trials. <i>Atherosclerosis</i> , 2015, 241, e190-e191.	0.4	4
679	Statin therapy and plasma coenzyme Q10 concentrations – A systematic review and meta-analysis of placebo-controlled trials. <i>Pharmacological Research</i> , 2015, 99, 329-336.	3.1	145
680	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2015, 132, 667-676.	1.6	41
681	The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension. <i>International Journal of Molecular Sciences</i> , 2015, 16, 10715-10733.	1.8	33
682	Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1391-1397.	1.4	36
683	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. <i>Atherosclerosis</i> , 2015, 242, 87-96.	0.4	47
684	Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. <i>Atherosclerosis</i> , 2015, 242, 243-250.	0.4	93

#	ARTICLE	IF	CITATIONS
685	Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. <i>Journal of Clinical Lipidology</i> , 2015, 9, 576-582.	0.6	56
686	In replyâ€”Coenzyme Q10 and Statin-Induced Myopathy. <i>Mayo Clinic Proceedings</i> , 2015, 90, 420-421.	1.4	9
687	Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors â€” Results from a systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2015, 189, 47-55.	0.8	138
688	Statin intolerance â€” an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955.	1.0	117
689	Sudden cardiac death in CKD patients. <i>International Urology and Nephrology</i> , 2015, 47, 971-982.	0.6	25
690	Is Blood Pressure Control for Stroke Prevention the Correct Goal?. <i>Stroke</i> , 2015, 46, 1595-1600.	1.0	62
691	Lipids, blood pressure and kidney update 2014. <i>Pharmacological Research</i> , 2015, 95-96, 111-125.	3.1	77
692	Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge. <i>International Urology and Nephrology</i> , 2015, 47, 805-813.	0.6	14
693	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015, 243, 257-259.	0.4	148
694	Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?. , 2015, , 179-190.		1
695	An evaluation of RVX-208 for the treatment of atherosclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1389-1398.	1.9	31
696	Analysis of vitamin D levels in patients with and without statin-associated myalgia â€” A systematic review and meta-analysis of 7 studies with 2420 patients. <i>International Journal of Cardiology</i> , 2015, 178, 111-116.	0.8	154
697	Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 603-606.	1.8	84
698	Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 753-761.	0.8	25
699	Contrasting Cholesterol Management Guidelines for Adults with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1173-1180.	3.0	52
700	Proprotein Convertase Subtilisin/Kexin 9 Inhibitors. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 157-168.	1.0	53
701	Effects of Established Hypolipidemic Drugs on HDL Concentration, Subclass Distribution, and Function. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 593-615.	0.9	22
702	Effects of statins on delirium following cardiac surgery â€” evidence from literature. <i>Psychiatria Polska</i> , 2015, 49, 1359-1370.	0.2	9

#	ARTICLE	IF	CITATIONS
703	Low Rates of Both Lipid-Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at High-Risk for Cardiovascular Disease across Europe. PLoS ONE, 2015, 10, e0115270.	1.1	25
704	Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials. Archives of Medical Science, 2015, 11, 915-26.	0.4	24
705	Statins and Fibrates: Should They Be Recommended?., 2015, , 11-23.		1
706	Editorial: Atrial Fibrillation after Coronary Surgery: The Need for an Effective Pharmacological Prophylaxis. Current Vascular Pharmacology, 2014, 11, 985-987.	0.8	2
707	Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey. Vascular Health and Risk Management, 2014, 10, 63.	1.0	1
708	Editorial (Thematic Issue: Current Research, Knowledge and Controversies on High Density) Tj ETQq0 0 0 rgBT /Overlock 10 Tj 50 542 To	1.2	2
709	Editorial (Thematic Issue: The Changing Face of Metabolic Syndrome and its Components in the Light) Tj ETQq1 1 0,784314 rgBT /Over	0.8	2
710	Markers of increased cardiovascular risk in patients with chronic kidney disease. Lipids in Health and Disease, 2014, 13, 135.	1.2	40
711	Novel anti-obesity drugs and plasma lipids. Clinical Lipidology, 2014, 9, 179-187.	0.4	7
712	Effect of Atorvastatin on Low-Density Lipoprotein Subpopulations and Comparison Between Indicators of Plasma Atherogenicity. Angiology, 2014, 65, 794-799.	0.8	16
713	Dysfunctional HDL: the journey from savior to slayer. Clinical Lipidology, 2014, 9, 49-59.	0.4	15
714	Club 35 Poster session 3: Friday 5 December 2014, 08:30-18:00 * Location: Poster area. European Heart Journal Cardiovascular Imaging, 2014, 15, ii154-ii160.	0.5	1
715	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. Journal of Hypertension, 2014, 32, 1741-1750.	0.3	39
716	Bedside Tool for Predicting the Risk of Postoperative Atrial Fibrillation After Cardiac Surgery: The POAF Score. Journal of the American Heart Association, 2014, 3, e000752.	1.6	130
717	New Obesity Indices and Adipokines in Normotensive Patients and Patients With Hypertension. Angiology, 2014, 65, 333-342.	0.8	33
718	Heart function disturbances in chronic kidney disease – echocardiographic indices. Archives of Medical Science, 2014, 6, 1109-1116.	0.4	30
719	Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 453-461.	2.2	64
720	Lipid, blood pressure and kidney update 2013. International Urology and Nephrology, 2014, 46, 947-961.	0.6	60

#	ARTICLE	IF	CITATIONS
721	Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. <i>Acta Diabetologica</i> , 2014, 51, 625-632.	1.2	30
722	Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study. <i>Lipids in Health and Disease</i> , 2014, 13, 29.	1.2	92
723	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014, 232, 346-360.	0.4	419
724	Should low high-density lipoprotein cholesterol (HDL-C) be treated?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 353-368.	2.2	61
725	Predictors of Insulin Resistance in Patients With Obesity. <i>Angiology</i> , 2014, 65, 22-30.	0.8	42
726	ETC-1002: A future option for lipid disorders?. <i>Atherosclerosis</i> , 2014, 237, 705-710.	0.4	36
727	Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. <i>International Journal of Cardiology</i> , 2014, 176, 219-226.	0.8	60
728	The Knowledge and Awareness of Hypertension Among Patients With Hypertension in Central Poland. <i>Angiology</i> , 2014, 65, 525-532.	0.8	10
729	Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease. <i>Drugs</i> , 2014, 74, 971-980.	4.9	46
730	Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum. <i>Journal of Clinical Lipidology</i> , 2014, 8, 173-180.	0.6	30
731	Influence of exercise training on T-wave alternans assessed during exercise test in heart failure patients. <i>International Journal of Cardiology</i> , 2014, 174, 747-749.	0.8	4
732	The effect of timing of cardiac catheterization on acute kidney injury after cardiac surgery is influenced by the type of operation. <i>International Journal of Cardiology</i> , 2014, 173, 46-54.	0.8	26
733	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient. <i>Journal of Hypertension</i> , 2014, 32, 1888-1897.	0.3	65
734	Hypertension and Prevention of Diastolic Heart Failure in the Aging Population. , 2014, , 35-45.		3
735	Assessment of the Relationship between Lipid Parameters and Obesity Indices in Non-Diabetic Obese Patients: A Preliminary Report. <i>Medical Science Monitor</i> , 2014, 20, 2683-2688.	0.5	29
736	Atherogenic Versus Non-atherogenic Lipoprotein Profiles in Healthy Individuals. Is There a Need to Change Our Approach to Diagnosing Dyslipidemia?. <i>Current Medicinal Chemistry</i> , 2014, 21, 2892-2901.	1.2	24
737	Can We Change the Functionality of HDL Cholesterol with Nonpharmacological and Pharmacological Agents?. <i>Current Medicinal Chemistry</i> , 2014, 21, 2927-2946.	1.2	23
738	Subfractions and Subpopulations of HDL: An Update. <i>Current Medicinal Chemistry</i> , 2014, 21, 2881-2891.	1.2	73

#	ARTICLE	IF	CITATIONS
739	Statins and New-Onset Diabetes. <i>Current Pharmaceutical Design</i> , 2014, 20, 3657-3664.	0.9	29
740	Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation. <i>Current Pharmaceutical Design</i> , 2014, 20, 4953-4960.	0.9	27
741	Pre-CKD- Do we Need Another Hero?. <i>Current Vascular Pharmacology</i> , 2014, 12, 642-648.	0.8	4
742	Patients with Prehypertension â€œ Do we have Enough Evidence to Treat them?. <i>Current Vascular Pharmacology</i> , 2014, 12, 586-597.	0.8	3
743	The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy â€œ 5-year follow-up. <i>Lipids in Health and Disease</i> , 2013, 12, 47.	1.2	25
744	Medication Management of Chronic Heart Failure in Older Adults. <i>Drugs and Aging</i> , 2013, 30, 765-782.	1.3	18
745	The risk of atherosclerosis in patients with chronic kidney disease. <i>International Urology and Nephrology</i> , 2013, 45, 1605-1612.	0.6	76
746	Renalase, Hypertension, and Kidney â€œ The Discussion Continues. <i>Angiology</i> , 2013, 64, 181-187.	0.8	18
747	Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey. <i>Atherosclerosis</i> , 2013, 231, 300-307.	0.4	66
748	Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. <i>Annals of Medicine</i> , 2013, 45, 37-50.	1.5	56
749	A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. <i>International Journal of Cardiology</i> , 2013, 168, 5437-5447.	0.8	66
750	Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2013, 126, 887-893.	0.6	42
751	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
752	Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: A prospective study. <i>Pharmacological Research</i> , 2013, 78, 41-48.	3.1	10
753	Blood Pressure Levels and Stroke: J-curve Phenomenon?. <i>Current Hypertension Reports</i> , 2013, 15, 575-581.	1.5	26
754	The effects of statins on blood pressure in normotensive or hypertensive subjects â€œ A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2013, 168, 2816-2824.	0.8	37
755	Heart failure biomarkers in patients with dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2013, 168, 2404-2410.	0.8	43
756	Prevention of heart failure in older adults may require higher levels of physical activity than needed for other cardiovascular events. <i>International Journal of Cardiology</i> , 2013, 168, 1905-1909.	0.8	34

#	ARTICLE	IF	CITATIONS
757	Stanowisko dotyczące postępowania w rodzinnej hipercholesterolemii u dzieci i młodzieży. Stanowisko Forum Ekspertów Lipidowych. <i>Pediatrics Polska</i> , 2013, 88, 567-574.	0.1	1
758	Metabolic syndrome and renal disease. <i>International Journal of Cardiology</i> , 2013, 164, 141-150.	0.8	74
759	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy: A meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013, 72, 35-44.	3.1	90
760	Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum. <i>Journal of Clinical Lipidology</i> , 2013, 7, 217-221.	0.6	28
761	Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. <i>International Journal of Cardiology</i> , 2013, 162, 73-76.	0.8	23
762	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	1.0	5,681
763	The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective. <i>Clinical Lipidology</i> , 2013, 8, 173-181.	0.4	24
764	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013, 29, 435-451.	0.9	36
765	Design and methodology of POWER, an open-label observation of the effect of primary care interventions on total cardiovascular risk in patients with hypertension. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 210-215.	1.0	6
766	Statins in patients with chronic kidney disease – an attempt at recommendations. <i>Current Medical Research and Opinion</i> , 2013, 29, 1419-1422.	0.9	9
767	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1281-1357.	0.3	4,251
768	Statin therapy and new-onset diabetes: an attempt at recommendations. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 213-216.	1.2	10
769	Letter on “Sodium-dependent modulation of systemic and urinary reninase expression and activity in the rat remnant kidney”. <i>Journal of Hypertension</i> , 2013, 31, 1272-1273.	0.3	3
770	State of the art paper Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. <i>Archives of Medical Science</i> , 2013, 1, 166-171.	0.4	25
771	State of the art paper Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. <i>Archives of Medical Science</i> , 2013, 6, 1019-1027.	0.4	25
772	Editorial Statin treatment in the elderly: how much do we know?. <i>Archives of Medical Science</i> , 2013, 4, 585-588.	0.4	8
773	Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease. <i>Medical Science Monitor</i> , 2013, 19, 954-959.	0.5	19
774	The Role of Fibrate Treatment in Dyslipidemia: An Overview. <i>Current Pharmaceutical Design</i> , 2013, 19, 3124-3131.	0.9	104

#	ARTICLE	IF	CITATIONS
775	Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. <i>Integrated Blood Pressure Control</i> , 2013, 6, 101.	0.4	20
776	PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3869-3877.	0.9	52
777	Obesity indices and adipokines in non-diabetic obese patients with early stages of chronic kidney disease. <i>Medical Science Monitor</i> , 2013, 19, 1063-1072.	0.5	37
778	Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists. <i>Current Pharmaceutical Design</i> , 2013, 19, 3816-3826.	0.9	7
779	Statin Therapy and New-onset Diabetes: Molecular Mechanisms and Clinical Relevance. <i>Current Pharmaceutical Design</i> , 2013, 19, 4904-4912.	0.9	62
780	Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3858-3868.	0.9	41
781	Acute Coronary Syndromes in Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , 2013, 11, 758-767.	0.8	18
782	Rationale of Statin Therapy in Septic Patients. <i>Current Vascular Pharmacology</i> , 2013, 11, 795-800.	0.8	9
783	Factors influencing post-coronary artery bypass grafting atrial fibrillation episodes. <i>Kardiologia Polska</i> , 2013, 71, 1115-1120.	0.3	10
784	Management of familial heterozygous hypercholesterolemia. Position paper of the Polish Lipid Expert Forum. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 7-10.	0.3	1
785	Management of familial heterozygous hypercholesterolemia. Position paper of the Polish Lipid Expert Forum. , 2013, 123, 7-10.		0
786	Statins and the Risk of Diabetes: The Debate. <i>Archives of Internal Medicine</i> , 2012, 172, 895-6; author reply 896-7.	4.3	13
787	Dronedaron: An overview. <i>Annals of Medicine</i> , 2012, 44, 60-72.	1.5	18
788	Hypertension therapy in the older adultsâ€”do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. <i>Journal of Human Hypertension</i> , 2012, 26, 641-643.	1.0	40
789	Do novel biomarkers add to existing scores of total cardiovascular risk?. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 14-17.	0.8	13
790	Statin use and risk of diabetes mellitus in postmenopausal women. <i>Clinical Lipidology</i> , 2012, 7, 267-270.	0.4	12
791	Hypertension and kidney disease. <i>Journal of Hypertension</i> , 2012, 30, 457-462.	0.3	20
792	An update on biomarkers of heart failure in hypertensive patients. <i>Journal of Hypertension</i> , 2012, 30, 1681-1689.	0.3	51

#	ARTICLE	IF	CITATIONS
793	Observations on Degenerative Changes Within the Optic Nerve in Patients With Primary Open Glaucoma and Arterial Hypertension: 6-Month Follow-Up. <i>Journal of Clinical Hypertension</i> , 2012, 14, 701-710.	1.0	4
794	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>Atherosclerosis</i> , 2012, 223, 1-68.	0.4	414
795	Polish Lipid Association "A strong response to the problem of lipid disorders in Poland and Central and Eastern Europe. <i>Journal of Clinical Lipidology</i> , 2012, 6, 105-107.	0.6	4
796	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>European Heart Journal</i> , 2012, 33, 1635-1701.	1.0	5,247
797	Right ventricular ejection fraction < 20% is an independent predictor of mortality but not of hospitalization in older systolic heart failure patients. <i>International Journal of Cardiology</i> , 2012, 155, 120-125.	0.8	17
798	The meaning of hypokalemia in heart failure. <i>International Journal of Cardiology</i> , 2012, 158, 12-17.	0.8	55
799	Prevention of sudden cardiac death in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2012, 13, 162.	0.8	27
800	Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?. <i>Progress in Lipid Research</i> , 2012, 51, 314-324.	5.3	187
801	PCV5 The Effects of Statins on Blood Pressure in Normotensive or Hypertensive Subjects-a Meta-Analysis of 18 Randomized Controlled Trials Involving 5628 Participants. <i>Value in Health</i> , 2012, 15, A629-A630.	0.1	0
802	Blood Pressure J-Curve: Current Concepts. <i>Current Hypertension Reports</i> , 2012, 14, 556-566.	1.5	90
803	Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. <i>Blood Pressure</i> , 2012, 21, 3-5.	0.7	46
804	Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 " a prospective study. <i>Archives of Medical Science</i> , 2012, 2, 227-235.	0.4	52
805	Editorial Lipid-lowering therapies and achievement of LDL-cholesterol targets. <i>Archives of Medical Science</i> , 2012, 4, 598-600.	0.4	17
806	Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients " pilot study. <i>Archives of Medical Science</i> , 2012, 3, 431-436.	0.4	37
807	Association between heart rate at rest and myocardial perfusion in patients with acute myocardial infarction undergoing cardiac rehabilitation " a pilot study. <i>Archives of Medical Science</i> , 2012, 4, 622-630.	0.4	10
808	Editorial The effects of statins on blood pressure: current knowledge and future perspectives. <i>Archives of Medical Science</i> , 2012, 1, 1-3.	0.4	10
809	Preoperative Statin Therapy Is Not Associated With a Decrease in the Incidence of Delirium After Cardiac Operations. <i>Annals of Thoracic Surgery</i> , 2012, 93, 1439-1447.	0.7	57
810	Lipids, Blood Pressure, Kidney-what was New in 2012?. <i>International Journal of Pharmacology</i> , 2012, 8, 659-678.	0.1	9

#	ARTICLE	IF	CITATIONS
811	Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients - pilot study. Archives of Medical Science, 2012, 8, 431-6.	0.4	51
812	Plant and animal protein intake and its association with overweight and obesity among the Belgian population. British Journal of Nutrition, 2011, 105, 1106-1116.	1.2	57
813	Imbalance between pro-angiogenic and anti-angiogenic factors in rheumatic and mixomatous mitral valves. International Journal of Cardiology, 2011, 152, 337-344.	0.8	10
814	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	1.0	2,767
815	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 1-44.	0.4	180
816	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 3-46.	0.4	561
817	Prognostic value of plasma N-terminal pro-B-type natriuretic peptide concentration in patients with normal and impaired left ventricular systolic function undergoing surgery for abdominal aortic aneurysm. Archives of Medical Science, 2011, 4, 642-647.	0.4	8
818	Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: Preliminary results. Medical Science Monitor, 2011, 17, PR13-PR18.	0.5	52
819	Relevance of 123 I-BMIPP delayed scintigraphic imaging for patients with angina pectoris – a pilot study. Archives of Medical Science, 2011, 3, 428-432.	0.4	5
820	State of the art papers Lipids, blood pressure, kidney – what was new in 2011?. Archives of Medical Science, 2011, 6, 1055-1066.	0.4	63
821	Malignancy-Associated Dyslipidemia. Open Cardiovascular Medicine Journal, 2011, 5, 35-40.	0.6	46
822	Left atrial size in hypertension and stroke. Journal of Hypertension, 2011, 29, 1988-1993.	0.3	36
823	Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. Journal of Hypertension, 2011, 29, 2493-2494.	0.3	24
824	Gender Differences in the Treatment of Ischemic Heart Disease. Current Pharmaceutical Design, 2011, 17, 1059-1069.	0.9	10
825	Optimal Timing of Discontinuation of Clopidogrel and Risk of Blood Transfusion After Coronary Surgery - Propensity Score Analysis -. Circulation Journal, 2011, 75, 2805-2812.	0.7	12
826	Correlation of the severity of diabetic retinopathy and the heart muscle perfusion in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2011, 25, 253-257.	1.2	6
827	Relation of Baseline Systolic Blood Pressure and Long-Term Outcomes in Ambulatory Patients With Chronic Mild to Moderate Heart Failure. American Journal of Cardiology, 2011, 107, 1208-1214.	0.7	92
828	What is the risk of hyperkalaemia in heart failure?. Expert Opinion on Pharmacotherapy, 2011, 12, 2329-2338.	0.9	8

#	ARTICLE	IF	CITATIONS
829	Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. <i>International Urology and Nephrology</i> , 2011, 43, 491-498.	0.6	33
830	The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 174-179.	0.8	46
831	Statins and dilated cardiomyopathy: do we have enough data?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 315-323.	1.9	18
832	What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1835-1844.	0.9	31
833	Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. <i>European Heart Journal</i> , 2011, 32, 2143-2152.	1.0	285
834	Reply to Preoperative n-3 Polyunsaturated Fatty Acids Do Not Reduce Postoperative Atrial Fibrillation in Cardiac Surgery, by Takagi I. and Umemoto T. <i>Angiology</i> , 2011, 62, 278-279.	0.8	1
835	Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease. <i>Journal of Nephrology</i> , 2011, 24, 717-722.	0.9	35
836	Dietary Sources of Fiber Intake and Its Association with Socio-Economic Factors among Flemish Preschool Children. <i>International Journal of Molecular Sciences</i> , 2011, 12, 1836-1853.	1.8	7
837	Significance of 99mTc-Sestamibi myocardial scintigraphy after percutaneous coronary intervention in patients with acute myocardial infarction. <i>Medical Science Monitor</i> , 2011, 17, CR140-CR145.	0.5	4
838	Erythropoietin update 2011. <i>Medical Science Monitor</i> , 2011, 17, RA240-RA247.	0.5	13
839	Should we have any doubts about hypertension therapy in elderly patients? ACCF/AHA 2011 expert consensus document on hypertension in the elderly. <i>Polish Archives of Internal Medicine</i> , 2011, 121, 253-258.	0.3	8
840	Should we have any doubts about hypertension therapy in elderly patients?: ACCF/AHA 2011 expert consensus document on hypertension in the elderly. , 2011, 121, 253-8.		13
841	Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E.)] <i>TJ ETQq1 1 0.784314 rgBT /Ov</i>	0.8	18
842	Clinical Implications of Non-Invasive Measurement of Central Aortic Blood Pressure. <i>Current Vascular Pharmacology</i> , 2010, 8, 747-752.	0.8	9
843	Postoperative Atrial Fibrillation - What Do We Really Know?. <i>Current Vascular Pharmacology</i> , 2010, 8, 553-572.	0.8	49
844	The Use of DSM-IV and ICD-10 Criteria and Diagnostic Scales for Delirium Among Cardiac Surgery Patients: Results From the IPDACS Study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2010, 22, 426-432.	0.9	36
845	Current Place of Beta-Blockers in the Treatment of Hypertension. <i>Current Vascular Pharmacology</i> , 2010, 8, 733-741.	0.8	23
846	Impact of Baseline Systolic Blood Pressure on Long-Term Outcomes in Patients With Advanced Chronic Systolic Heart Failure (Insights from the BEST Trial). <i>American Journal of Cardiology</i> , 2010, 106, 221-227.	0.7	44

#	ARTICLE	IF	CITATIONS
847	Statin therapy in the elderly: A review. Archives of Gerontology and Geriatrics, 2010, 50, 114-118.	1.4	47
848	Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties. International Journal of Clinical Practice, 2010, 64, 1148-1154.	0.8	7
849	Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide. A pilot study. Archives of Medical Science, 2010, 4, 513-518.	0.4	26
850	Editorial Are we getting to lipid targets in real life?. Archives of Medical Science, 2010, 5, 639-641.	0.4	17
851	Effectiveness comparison of endoscopic methods of non-varicose upper gastrointestinal bleeding treatment. Archives of Medical Science, 2010, 4, 599-604.	0.4	2
852	Progression of diabetic retinopathy correlated with muscle perfusion disturbances of the lower limbs, with clinically important diagnostic recommendations. Archives of Medical Science, 2010, 6, 904-911.	0.4	2
853	Left atrial and left atrial appendage systolic function in patients with post-myocardial distal blocks. Archives of Medical Science, 2010, 6, 892-899.	0.4	6
854	Prevention of cardiovascular disease in asymptomatic people. Heart, 2010, 96, 477-482.	1.2	3
855	Heart Rate Control in an Unselected Consecutive Population of Outpatients With Stable Coronary Artery Disease: Analysis of the CARDIf Study Cohort. Angiology, 2010, 61, 763-767.	0.8	14
856	Preoperative n-3 Polyunsaturated Fatty Acids Are Associated With a Decrease in the Incidence of Early Atrial Fibrillation Following Cardiac Surgery. Angiology, 2010, 61, 643-650.	0.8	54
857	Morphine-mediated alteration of hypertension-related gene expression in human white blood cells and multilineage progenitor cells. Journal of Human Hypertension, 2010, 24, 713-720.	1.0	8
858	Are Polymorphisms within Endothelial Nitric Oxide Synthase Good Predictors of Coronary Artery Disease. Cardiology, 2010, 116, 268-270.	0.6	1
859	Lone atrial fibrillation: what do we know?. Heart, 2010, 96, 498-503.	1.2	50
860	Statins in patients with chronic kidney disease: why, who and when?. Expert Opinion on Pharmacotherapy, 2010, 11, 2665-2674.	0.9	24
861	Angiotensin converting-enzyme inhibitors and candesartan have no effects on atrial fibrillation after cardiac surgery. International Journal of Cardiology, 2010, 142, 209-210.	0.8	4
862	Takotsubo cardiomyopathy – The current state of knowledge. International Journal of Cardiology, 2010, 142, 120-125.	0.8	78
863	Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. Journal of Psychosomatic Research, 2010, 69, 179-185.	1.2	217
864	The role of Toll-like receptors in renal diseases. Nature Reviews Nephrology, 2010, 6, 224-235.	4.1	168

#	ARTICLE	IF	CITATIONS
865	Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study. <i>Lipids in Health and Disease</i> , 2010, 9, 21.	1.2	10
866	Current problems in hypertension and nephrology. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2575-2578.	0.9	28
867	The Role of Polymorphisms Within Paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the Modulation of Cardiovascular Risk: A Pilot Study. <i>Angiology</i> , 2010, 61, 157-165.	0.8	42
868	The role of polyphenols in cardiovascular disease. <i>Medical Science Monitor</i> , 2010, 16, RA110-9.	0.5	35
869	High sensitivity C-reactive protein, NT-proBNP and hemodynamic left ventricular function in acute coronary syndrome without ST segment elevation - a preliminary report. <i>Medical Science Monitor</i> , 2010, 16, CR313-7.	0.5	3
870	The behaviour of bone mineral density and bone metabolism index in young and menopausal women with the consideration of body mass index. <i>Medical Science Monitor</i> , 2010, 16, CR342-7.	0.5	4
871	Assessment of blood flow in posterior ciliary arteries and its correlation with intraocular and arterial blood pressures in patients with open angle glaucoma. <i>Medical Science Monitor</i> , 2010, 16, CR501-9.	0.5	7
872	Relative Validity and Reproducibility of a Food-Frequency Questionnaire for Estimating Food Intakes among Flemish Preschoolers. <i>International Journal of Environmental Research and Public Health</i> , 2009, 6, 382-399.	1.2	84
873	Vernakalant hydrochloride for the treatment of atrial fibrillation. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1929-1937.	1.9	15
874	Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 652-659.	2.1	174
875	EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 121-137.	3.1	677
876	Aortic stiffness in diabetes mellitus – association with glutamine and heat shock protein 70 expression: a pilot study based on an experimental rodent model. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 267-274.	1.5	12
877	New European guidelines for cardiovascular disease prevention in clinical practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 138-42.	1.4	12
878	Natriuretic Peptides in Septic Patients. <i>Current Medicinal Chemistry</i> , 2009, 16, 4020-4031.	1.2	13
879	Plasma Total Antioxidant Activity in Comparison with Plasma NO and VEGF Levels in Patients with Metabolic Syndrome. <i>Angiology</i> , 2009, 60, 87-92.	0.8	34
880	Effects of Atorvastatin on Vascular Intimal Hyperplasia: An Experimental Rodent Model. <i>Angiology</i> , 2009, 60, 370-377.	0.8	24
881	Percutaneous Coronary Interventions Affect Concentrations of Interleukin 6 and Its Soluble Receptors in Coronary Sinus Blood in Patients with Stable Angina. <i>Angiology</i> , 2009, 60, 322-328.	0.8	5
882	Predictive factors for endoleaks after thoracic aortic aneurysm endograft repair. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 138, 880-885.	0.4	43

#	ARTICLE	IF	CITATIONS
883	The mechanisms of atrial fibrillation in hyperthyroidism. <i>Thyroid Research</i> , 2009, 2, 4.	0.7	85
884	Arteriovenous Fistula Leading to Severe Tortuosity and Aneurysm Formation. <i>Journal of Cardiac Surgery</i> , 2009, 24, 109-109.	0.3	1
885	HSP 70 and atherosclerosis – protector or activator?. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 307-317.	1.5	46
886	The Clinical Manifestation of Myocardial Infarction in Elderly Patients. <i>Clinical Cardiology</i> , 2009, 32, E46-51.	0.7	49
887	The concentration of uric acid in patients with metabolic syndrome and cardiovascular diseases. <i>Open Medicine (Poland)</i> , 2009, 4, 272-278.	0.6	2
888	Endothelial Dysfunction in Patients with Noncomplicated and Complicated Hypertension. <i>Clinical and Experimental Hypertension</i> , 2009, 31, 20-30.	0.5	24
889	Is Polymorphism within <i>eNOS</i> Gene Associated With the Late Onset of Myocardial Infarction? A Pilot Study. <i>Angiology</i> , 2009, 60, 588-595.	0.8	21
890	Nephroprotective and clinical potential of statins in dialyzed patients. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 541-550.	1.5	38
891	Role and significance of statins in the treatment of hypertensive patients. <i>Current Medical Research and Opinion</i> , 2009, 25, 1995-2005.	0.9	40
892	Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. <i>Lancet, The</i> , 2009, 373, 929-940.	6.3	737
893	Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases. <i>Medical Science Monitor</i> , 2009, 15, 203-208.	0.5	37
894	Atrial Fibrillation: The New Epidemic of the Ageing World. <i>Journal of Atrial Fibrillation</i> , 2009, 1, 154.	0.5	21
895	Atrial Fibrillation: The New Epidemic of the Ageing World. <i>Journal of Atrial Fibrillation</i> , 2009, 1, .	0.5	10
896	Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors. <i>In Vivo</i> , 2009, 23, 797-812.	0.6	19
897	Time for new indications for statins?. <i>Medical Science Monitor</i> , 2009, 15, MS1-5.	0.5	51
898	The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. <i>Medical Science Monitor</i> , 2009, 15, MS12-23.	0.5	36
899	Ticagrelor—a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?. <i>Medical Science Monitor</i> , 2009, 15, MS24-30.	0.5	22
900	Left ventricular dysfunction and NT-proBNP levels in patients with one-vessel disease after first ST-elevation myocardial infarction treated with primary coronary angioplasty. <i>Kardiologia Polska</i> , 2009, 67, 1201-6.	0.3	5

#	ARTICLE	IF	CITATIONS
901	IL-2, IL-6 and IL-8 levels remain unaltered in the course of immunosuppressive therapy after renal transplantation. <i>Open Medicine (Poland)</i> , 2008, 3, 199-202.	0.6	0
902	Mortality in surgical units and postoperative care. <i>Open Medicine (Poland)</i> , 2008, 3, 346-357.	0.6	0
903	Natriuretic peptides in cardiovascular diseases. <i>Cellular and Molecular Biology Letters</i> , 2008, 13, 155-81.	2.7	36
904	Carvedilol modifies antioxidant status of patients with stable angina. <i>Cellular and Molecular Biology Letters</i> , 2008, 13, 230-9.	2.7	12
905	Dofetilide for the Prevention of Postoperative Atrial Fibrillation After Coronary Surgery: Is It a Useful Routine Prophylaxis?. <i>American Journal of Cardiology</i> , 2008, 102, 506.	0.7	3
906	Endovascular treatment of mycotic aortic aneurysms. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 135, 1404.	0.4	2
907	Statins in the prevention of postoperative atrial fibrillation: Is there really no effect?. <i>American Heart Journal</i> , 2008, 155, e53.	1.2	16
908	Obesity and postoperative atrial fibrillation. Is there no connection?. <i>American Heart Journal</i> , 2008, 156, e5.	1.2	5
909	Detection of infectious agents by polymerase chain reaction in human aortic wall. <i>Cardiovascular Pathology</i> , 2008, 17, 297-302.	0.7	39
910	LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN SUBJECTS WITH METABOLIC SYNDROME. <i>Atherosclerosis Supplements</i> , 2008, 9, 232.	1.2	2
911	Clinical Utility and Use of DSM-IV and ICD-10 Criteria and The Memorial Delirium Assessment Scale in Establishing a Diagnosis of Delirium After Cardiac Surgery. <i>Psychosomatics</i> , 2008, 49, 73-76.	2.5	35
912	The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation—still underestimated opponent. <i>Europace</i> , 2008, 10, 1266-1270.	0.7	44
913	Does Gender Influence the Patency of Infrainguinal Bypass Grafts?. <i>Angiology</i> , 2008, 59, 278-282.	0.8	13
914	Relation Between Postoperative Mortality and Atrial Fibrillation Before Surgical Revascularization - 3-Year Follow-Up. <i>Thoracic and Cardiovascular Surgeon</i> , 2008, 56, 20-23.	0.4	36
915	Effect of Cardiovascular Drugs on Adenosine Deaminase Activity. <i>Angiology</i> , 2008, 59, 740-744.	0.8	9
916	1344 Time trends in smoking in coronary patients the EUROASPIRE surveys I, II and III in 8 countries. <i>European Journal of Cardiovascular Nursing</i> , 2008, 7, 25-26.	0.4	1
917	Atrial Fibrillation After Isolated Coronary Surgery Affects Late Survival. <i>Circulation</i> , 2008, 118, 1612-1618.	1.6	268
918	Letter by Banach et al Regarding Article, "Postoperative Treatment With Carvedilol, a β^2 -Adrenergic Blocker, Prevents Paroxysmal Atrial Fibrillation After Coronary Artery Bypass Grafting". <i>Circulation Journal</i> , 2008, 72, 1388.	0.7	4

#	ARTICLE	IF	CITATIONS
919	Comparison of Transperitoneal and Retroperitoneal Approaches in Abdominal Aortic Surgery. <i>Acta Chirurgica Belgica</i> , 2008, 108, 557-562.	0.2	14
920	The Role of Trimetazidine After Acute Myocardial Infarction. <i>Current Vascular Pharmacology</i> , 2008, 6, 282-291.	0.8	10
921	Food Intakes by Preschool Children in Flanders Compared with Dietary Guidelines. <i>International Journal of Environmental Research and Public Health</i> , 2008, 5, 243-257.	1.2	59
922	Papaverine solution improves preservation of saphenous vein grafts used during cardiac surgery. <i>Acta Cardiologica</i> , 2008, 63, 445-449.	0.3	7
923	Atrial fibrillation as a nonpsychiatric predictor of delirium after cardiac surgery: a pilot study. <i>Medical Science Monitor</i> , 2008, 14, CR286-291.	0.5	20
924	Efficacy of remote ischaemic preconditioning for spinal cord protection against ischaemic injury: association with heat shock protein expression. <i>Folia Neuropathologica</i> , 2008, 46, 204-12.	0.5	24
925	Atrial and Brain Natriuretic Peptide and Endothelin-1 Concentration in Patients with Idiopathic Arterial Hypertension: The Dependence on the Selected Morphological Parameters. <i>Clinical and Experimental Hypertension</i> , 2007, 29, 149-164.	0.5	23
926	Echocardiographic Evaluation of the Left Atrium and Left Atrial Appendage Function in Patients with Atrial Septum Aneurysm - Implications for Thromboembolic Complications. <i>Thoracic and Cardiovascular Surgeon</i> , 2007, 55, 365-370.	0.4	13
927	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) <i>Tj ETQq1 1 0.784314 0.95 BT / Over</i>	0.7	14
928	2007 Guidelines for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1105-1187.	0.3	4,778
929	eComment: The anastomosis between aorta and extension conduit of the pulmonary artery. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2007, 7, 194-194.	0.5	2
930	Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 340-345.	3.1	0
931	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1751-1762.	0.3	1,152
932	Plasma Endothelin-1 Levels in Septic Patients. <i>Journal of Intensive Care Medicine</i> , 2007, 22, 232-239.	1.3	588
933	Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2007, 1770, 1651-1659.	1.1	24
934	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) <i>Tj ETQq0 0 0.1gBT / Overblock 10 T</i>	0.1	10
935	The SCORE model in the POWER study: an attempt to focus the limited resources for prevention on patients with greatest need. <i>Current Medical Research and Opinion</i> , 2007, 23, S19-S24.	0.9	5
936	Increased Exhaled H ₂ O ₂ and Impaired Lung Function in Patients Undergoing Bioincompatible Hemodialysis. <i>International Journal of Artificial Organs</i> , 2007, 30, 879-888.	0.7	10

#	ARTICLE	IF	CITATIONS
937	Predictors of paroxysmal atrial fibrillation in patients undergoing aortic valve replacement. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 134, 1569-1576.	0.4	57
938	N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients. <i>Cellular and Molecular Biology Letters</i> , 2007, 12, 162-75.	2.7	17
939	Evaluation of selected parameters of the antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2007, 55, 335-340.	1.0	12
940	92 Low BMI as an independent risk factor of death in patients with severe heart failure subjected to aortic valve replacement. <i>European Journal of Heart Failure, Supplement</i> , 2007, 6, 21-21.	0.2	0
941	Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. <i>Journal of Nephrology</i> , 2007, 20, 444-52.	0.9	66
942	The concentration of atrial and brain natriuretic peptide in patients with idiopathic hypertension. <i>Medical Science Monitor</i> , 2007, 13, CR449-56.	0.5	6
943	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2006, 28, 1462-1536.	1.0	1,617
944	Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. <i>European Heart Journal</i> , 2006, 27, 1341-1381.	1.0	1,192
945	P3-49. <i>Heart Rhythm</i> , 2006, 3, S193-S194.	0.3	0
946	Anti-oxidant activity of spermine and spermidine re-evaluated with oxidizing systems involving iron and copper ions. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 69-81.	1.2	30
947	Risk Factors of Atrial Fibrillation Following Coronary Artery Bypass Grafting. <i>Circulation Journal</i> , 2006, 70, 438-441.	0.7	118
948	TNF- α priming effect on polymorphonuclear leukocyte reactive oxygen species generation and adhesion molecule expression in hemodialyzed patients. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2006, 54, 209-215.	1.0	8
949	Increased whole blood chemiluminescence in patients with chronic renal failure independent of hemodialysis treatment. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2006, 54, 347-355.	1.0	12
950	Preoperative predictors of delirium after cardiac surgery: a preliminary study. <i>General Hospital Psychiatry</i> , 2006, 28, 536-538.	1.2	92
951	N-TERMINAL BRAIN NATRIURETIC PROPEPTIDE LEVELS CORRELATE WITH PROCALCITONIN AND C-REACTIVE PROTEIN LEVELS IN SEPTIC PATIENTS. <i>Shock</i> , 2006, 26, 36.	1.0	0
952	Neutrophil Superoxide Anion Generation During Atorvastatin and Fluvastatin Therapy Used in Coronary Heart Disease Primary Prevention. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 48, 143-147.	0.8	37
953	Increased Levels of Soluble TNF- α Receptors and Cellular Adhesion Molecules in Patients Undergoing Bioincompatible Hemodialysis. <i>American Journal of Nephrology</i> , 2006, 26, 437-444.	1.4	21
954	Risk Factors for Atrial Fibrillation in Adult Patients in Long-Term Observation Following Surgical Closure of Atrial Septal Defect Type II. <i>Thoracic and Cardiovascular Surgeon</i> , 2006, 54, 259-263.	0.4	13

#	ARTICLE	IF	CITATIONS
955	Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cellular and Molecular Immunology, 2006, 3, 151-4.	4.8	75
956	L-arginine improves hemodynamic function and coronary flow in an experimental model of ischemia-reperfusion injury. Annals of Transplantation, 2006, 11, 28-34.	0.5	7
957	NT-proBNP levels correlate with organ failure in septic patients: a preliminary report. Postepy Higieny I Medycyny Doswiadczalnej, 2006, 60, 632-6.	0.1	1
958	Increased hydrogen peroxide in the exhaled breath of uraemic patients unaffected by haemodialysis. Nephrology Dialysis Transplantation, 2004, 19, 158-163.	0.4	20
959	European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force Of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Archives Des Maladies Du Coeur Et Des Vaisseaux, 2004, 97, 1019-30.	0.3	14
960	Perceptions of job insecurity and the impact of world market competition as health risks: Results from Belstress. Journal of Occupational and Organizational Psychology, 2003, 76, 411-425.	2.6	32
961	Job stress among middle-aged health care workers and its relation to sickness absence. Stress and Health, 2003, 19, 265-274.	1.4	32
962	Effects of uraemia and haemodialysis on neutrophil apoptosis and expression of apoptosis-related proteins. Nephrology Dialysis Transplantation, 2003, 18, 2582-2588.	0.4	37
963	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European Heart Journal, 2003, 24, 1601-1610.	1.0	1,588
964	European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, S1-S10.	3.1	152
965	Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II. Atherosclerosis Supplements, 2002, 2, 13-17.	1.2	22
966	Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. Journal of the American College of Cardiology, 2000, 36, 766-772.	1.2	119
967	Epidemiology of Risk Factors for Hypertension. Drugs, 1999, 57, 695-712.	4.9	46
968	A Comparison of Lifestyle, Genetic, Bioclinical and Biochemical Variables of Offspring with and without Family Histories of Premature Coronary Heart Disease: The Experience of the European Atherosclerosis Research Studies. European Journal of Cardiovascular Prevention and Rehabilitation, 1999, 6, 183-188.	3.1	15
969	Nutrient and food intakes in selected subgroups of Belgian adults. British Journal of Nutrition, 1999, 81, S37-S42.	1.2	27
970	Is Low Serum Chloride Level a Risk Factor for Cardiovascular Mortality?. European Journal of Cardiovascular Prevention and Rehabilitation, 1998, 5, 177-184.	3.1	15
971	Prevention of coronary heart disease in clinical practice: Summary of Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network. 1.2 The full text of the Recommendations was published simultaneously in the European Heart Journal 1998;19:1434a-e*1503. Atherosclerosis, 1998, 141, 1-10.	0.4	355
972	The Effect of Age and Lifestyle Factors on Plasma Levels of Apolipoprotein E. European Journal of Cardiovascular Prevention and Rehabilitation, 1998, 5, 155-159.	3.1	0

#	ARTICLE	IF	CITATIONS
973	LCZ696 (sacubitril/valsartan) for patients with heart failure. The Cochrane Library, 0, , .	1.5	0
974	Post-discharge and long-term follow-up after an acute coronary syndrome: International Collaborative Group of CNCF position paper.. Archives of Medical Science, 0, , .	0.4	5
975	Towards more personalized low-density lipoprotein-cholesterol lowering strategies in patients with atherosclerotic cardiovascular disease. European Journal of Preventive Cardiology, 0, , .	0.8	0
976	Non-alcoholic Fatty Liver Disease, Metabolic syndrome, and Type 2 diabetes mellitus: Where do we stand today?. Archives of Medical Science, 0, , .	0.4	1
977	Evaluation of miRNA-27a/b expression in patients with familial hypercholesterolemia. Archives of Medical Science, 0, , .	0.4	0
978	The effect of PCSK9 immunization on the hepatic level of microRNAs associated with PCSK9/LDLR pathway.. Archives of Medical Science, 0, , .	0.4	0